US8977365B2 - Electronic system for influencing cellular functions in a warm-blooded mammalian subject - Google Patents

Electronic system for influencing cellular functions in a warm-blooded mammalian subject Download PDF

Info

Publication number
US8977365B2
US8977365B2 US13/573,104 US201213573104A US8977365B2 US 8977365 B2 US8977365 B2 US 8977365B2 US 201213573104 A US201213573104 A US 201213573104A US 8977365 B2 US8977365 B2 US 8977365B2
Authority
US
United States
Prior art keywords
frequencies
treatment
amplitude modulation
follows
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/573,104
Other versions
US20130079853A1 (en
Inventor
Boris Pasche
Alexandre Barbault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THERABIONIC LLC
Original Assignee
THERABIONIC LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THERABIONIC LLC filed Critical THERABIONIC LLC
Priority to US13/573,104 priority Critical patent/US8977365B2/en
Publication of US20130079853A1 publication Critical patent/US20130079853A1/en
Assigned to THERABIONIC, LLC reassignment THERABIONIC, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARBAULT, ALEXANDRE, MR., PASCHE, BORIS, MR.
Application granted granted Critical
Publication of US8977365B2 publication Critical patent/US8977365B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/40Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/02Radiation therapy using microwaves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/02Radiation therapy using microwaves
    • A61N5/022Apparatus adapted for a specific treatment

Definitions

  • This invention relates to an electronic system for influencing cellular functions in a warm-blooded mammalian subject. More particularly, the invention concerns research findings related to how earlier electronic systems may be modified and programmed to achieve both improved and additional therapeutic effects.
  • the direct or indirect influence on cancerous cell growth may involve but is not necessarily limited to any of prophylactic avoidance of cancerous cell formation, influencing of cell functions such as for example influencing leukocyte cell functions which can lead to inhibition of cancerous cell growth or proliferation thereof, and/or killing of cancerous cells harboured by a warm-blooded mammalian subject.
  • Electromagnetic energy generating devices and use of electromagnetic energies for treating living mammalian subjects harbouring cancerous cells described in the literature include: U.S. Pat. No. 5,908,441 issued Jun. 1, 1999 to James E. Bare and the references cited therein and so-called “NovoCure technology” involving in vivo implantation of electrodes to either side of tumorous growths.
  • This literature does not contemplate very low energy emissions of electromagnetic energy involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
  • U.S. Pat. No. 5,690,692 issued Nov. 25, 1997 entitled “Bio-Active Frequency Generator and Method” describes a programmable control which instructs a frequency synthesizer to enable generation of an electrical current at a specific precise frequency signal or at a series of specific precise frequency signals having a square wave form to within an accuracy of 0.001 Hz.
  • This patent contemplates amplifying the voltage of the generated signals and applying the signals to a subject at the specific precise frequency or sequentially at the series of specific precise frequencies by means of electrodes held by or otherwise connected to the subject (which may be a mammal or a food).
  • this patent does not contemplate very low energy emissions involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
  • an electronic system which is activatable by electrical power.
  • the system is employed to influence cellular functions or malfunctions in a warm-blooded mammalian subject.
  • the system comprises one or more controllable low energy electromagnetic energy generator circuits for generating one or more high frequency radio frequency RF carrier signals.
  • One or more microprocessors or integrated circuits comprising or communicating with the one or more generator circuits are provided which are also for receiving control information from a source of programmed control information.
  • the one or more generator circuits include one or more amplitude modulation control signal generators for controlling amplitude modulated variations of the one or more high frequency carrier signals.
  • the one or more generator circuits furthermore include one or more programmable amplitude modulation frequency control signal generators for controlling the frequency at which the amplitude modulations are generated.
  • the one or more amplitude modulation frequency control generators are, in terms of an important improvement of the present invention, adapted to accurately control the frequency of the amplitude modulations to within an accuracy of at least 1000 parts per million (ppm) relative to one or more determined or predetermined reference amplitude modulation frequencies selected from within a range of 0.01 Hz to 150 kHz.
  • the system furthermore comprises a connection or coupling position for connection or coupling to or being connected or coupled to an electrically conductive applicator for applying to the warm-blooded mammalian subject the one or more amplitude-modulated low energy emissions at said accurately controlled modulation frequencies.
  • the term, “accurately controlled” means that the modulated low energy electromagnetic emissions should be modulated to within a resolution of at most about 1 Hz of intended higher frequencies (greater than about 1000 Hz) determined or predetermined modulation frequencies. For example, if one of the one or more determined or predetermined modulation frequencies to be applied to the warm-blooded mammalian subject is about 2000 Hz, the accurate control should lead to such modulated low energy emission being generated at a frequency of between about 1999 and about 2001 Hz.
  • the accurate control should lead to a resolution of about 0.5, more preferably about 0.1, yet more preferably about 0.01 and indeed most preferably about 0.001 Hz of the intended determined or predetermined modulation frequency.
  • the specific absorption rate should be and is most preferably substantially less than 1.6 milliW/g weight of living tissue.
  • the system includes a microprocessor (which may more recently be replaced by an integrated circuit) into which control information is loaded from an application storage device.
  • the microprocessor (or now alternatively integrated circuit) then controls the function of the system to produce the desired therapeutic emissions.
  • an impedance transformer connected intermediate the emitter of low energy electromagnetic emissions and a probe (here more broadly described as an electrically conductive applicator) for applying the emissions to the patient.
  • the impedance transformer substantially matches the impedance of the patient seen from the emitter circuit with the impedance of the output of the emitter circuit.
  • FIG. 1 shows an exemplary casing structure for the electronic circuit shown in FIG. 2 , an applicator 13 (exemplified as a probe suitable for being placed in the mouth of a patient) and an interface 16 (which may be replaced by a receiver) for receiving information from a source of information 52 such as may be comprised in an information storage device, e.g., of the nature described and illustrated in FIGS. 12 to 17 of EP 0 592 851 B1.
  • a source of information 52 such as may be comprised in an information storage device, e.g., of the nature described and illustrated in FIGS. 12 to 17 of EP 0 592 851 B1.
  • FIG. 2 is a block diagram of exemplary circuitry which may be comprised in the exemplary casing structure of FIG. 1 .
  • This FIG. 2 differs essentially from FIG. 2 of EP 0 592 851 B1 by comprising a highly accurate modulation frequency generator 31 (named a Digital Direct Synthesizer or DDS), which enables accurate control of modulatable oscillator represented by dotted line block 106 .
  • DDS Digital Direct Synthesizer
  • FIG. 3 of EP 0 592 851 B1 is a detailed schematic of a modulation signal generator 31 , replaced by a DDS modulation frequency generator 31 comprised in the circuit of present FIG. 2 .
  • FIG. 4 of EP 0 592 851 B1 is a detailed schematic of a modulation signal buffer and carrier oscillator circuit which may be employed in the circuit of the present FIG. 2 .
  • FIG. 5 of EP 0 592 851 B1 is a detailed schematic example of an amplitude modulation (AM) and power generator 34 and output filter 39 which could be comprised in the circuit of the present FIG. 2 .
  • AM amplitude modulation
  • FIG. 6 of EP 0 592 851 B1 is a detailed schematic example of an impedance transformer 14 which may be comprised in the circuit of the present FIG. 2 .
  • FIG. 7 of EP 0 592 851 B1 is a detailed schematic example of an emission sensor 53 which may be comprised in the circuit of the present FIG. 2 .
  • FIG. 8 of EP 0 592 851 B1 is a detailed schematic example of an output power sensor circuit 54 which may be employed in the circuit of the present FIG. 2 .
  • FIG. 9 of EP 0 592 851 B1 is a detailed schematic example of a display module or information output 17 which may be included in the circuit of the present FIG. 2 .
  • FIG. 10 of EP 0 592 851 B1 is a detailed schematic example of a power supply control circuit including battery charger 57 which may be comprised in the circuit of the present FIG. 2 .
  • FIGS. 11 a - d of EP 0 592 851 B1 are exemplary flow charts of the method of operation of the system of FIGS. 1 and 2 .
  • FIG. 1 presented is a modulated low energy electromagnetic emission application system 11 , in accordance with the present invention.
  • a modulated low energy electromagnetic emission application system 11 As described in prior U.S. Pat. Nos. 4,649,935 and 4,765,322, such a system has proven to be useful in the practice of Low Energy Emission Therapy (LEET, a trademark of Symtonic S.A. or a successor of this Company), which involves application of emissions of low energy radio frequency (RF) electromagnetic waves to a warm-blooded mammalian subject.
  • LEET Low Energy Emission Therapy
  • RF radio frequency
  • the application has proven to be an effective mode of treating a warm-blooded mammalian subject suffering from central nervous system (CNS) disorders such as, for example, generalized anxiety disorders, panic disorders, sleep disorders including insomnia, psychiatric disorders such as depression, obsessive compulsive disorders, disorders resulting from substance abuse, sociopathy, post traumatic stress disorders or other disorders of the central nervous system and combinations thereof.
  • CNS central nervous system
  • the system includes an electrically conductive applicator 12 , 13 for applying one or more electromagnetic emissions to the warm-blooded mammalian subject.
  • One form of applicator may consist of an electrically conductive probe or mouthpiece 13 which is inserted into the mouth of a subject undergoing treatment. Probe 13 is connected to an electromagnetic energy emitter (see also FIG. 2 ), through coaxial cable 12 and impedance matching transformer 14 .
  • An example of a coupling found to be effective involving indirect physical contact with the skin of a patient is an insulated applicator to be placed over or within an ear of the patient.
  • the emissions thus passed to the patient may be either by capacitive or radiated means or by a combination of both.
  • Electronic system 11 also includes a connector or coupler for connection to a programmable device such as a computer or an interface or receiver 16 which is adapted to receive an application storage device 52 such as, for example, magnetic media, semiconductor media, optical media or mechanically encoded media, or programmed emissions programmed with control information employed to control the operation of system 11 so that the desired type of low energy emission therapy is applied to the patient.
  • a programmable device such as a computer or an interface or receiver 16 which is adapted to receive an application storage device 52 such as, for example, magnetic media, semiconductor media, optical media or mechanically encoded media, or programmed emissions programmed with control information employed to control the operation of system 11 so that the desired type of low energy emission therapy is applied to the patient.
  • Application storage device 52 can be provided with a microprocessor which, when applied to interface 16 , operates to control the function of system 11 to apply the desired low energy emission therapy.
  • application storage device 52 can be provided with a microprocessor which is used in combination with microprocessor 21 within system 11 .
  • the microprocessor within device 52 could assist in the interfacing of storage device 52 with system 11 , or could provide security checking functions.
  • System 11 may also include a display 17 which can display various indications of the operation of system 11 .
  • system 11 may include on and off power buttons 18 and 19 , optionally replaced by user interface 21 A (refer to FIG. 2 ).
  • FIG. 2 presented is a block diagram of exemplary electronic circuitry of system 11 , in accordance with the present invention.
  • a data processor such as for example, microprocessor or integrated circuit 21 , operates as the controller for electronic system 11 , and is connected to control the various components of the system 11 , for example, through address bus 22 , data bus 23 and input/output lines 25 .
  • the block diagram of FIG. 2 is modified as compared to FIG. 2 of EP 0 592 851 B1 by including what is known as a digital direct synthesizer (DDS) 31 which operates as an accurate and stable modulation frequency generator within the system 11 .
  • DDS digital direct synthesizer
  • An exemplary DDS device is available from Analog Devices of Norwood, Mass. 02062-9106, USA, Part No. AD9835.
  • the device is a numerically controlled oscillator and modulation capabilities are provided for phase modulation and frequency modulation.
  • dotted line block 102 entitled “PROCESSOR WITH DAC”, the functionality of the DDS may also be combined with microprocessor 21 with digital to analogue converter (DAC).
  • DAC digital to analogue converter
  • Microprocessor 21 preferably includes internal storage for the operation of a coded control program, and temporary data.
  • microprocessor 21 may include input/output ports and internal timers.
  • Microprocessor 21 may be a microcontroller, for example microcontrollers 8048 or 8051 available from Intel Corporation of Santa Clara, Calif. 95054-1549, USA.
  • microprocessor 21 The timing for microprocessor 21 is provided by system clock oscillator 26 A which may be run at any clock frequency suitable for the particular type of microprocessor used.
  • An exemplary clock frequency is about 8.0 MHz.
  • Oscillator 26 A may be replaced by reference frequency oscillator 26 which secures the stability of the accurate modulation frequency.
  • RF (radio frequency) oscillator 32 may also be employed for this purpose.
  • a combination of oscillators is represented by dotted line block 104 , entitled “OSCILLATOR”.
  • microprocessor 21 functions to control controllable electromagnetic energy generator circuit 29 to produce a desired form of modulated low energy electromagnetic emission for application to a subject through applicator or probe 13 .
  • Dotted line block 29 entitled CONTROLLABLE GENERATOR, includes DDS modulation frequency generator 31 and carrier signal oscillator 32 .
  • Microprocessor 21 operates to activate or de-activate controllable generator circuit 29 through oscillator disable line 33 , as described in greater detail in EP 0 592 851 B1.
  • Controllable generator circuit 29 also includes an AM modulator and power generator 34 which operates to amplitude modulate a carrier signal produced by carrier oscillator 32 on carrier signal line 36 , with a modulation signal produced by modulation signal generator circuit 31 on modulation signal line 37 .
  • the combination of the functionality of the DDS modulation frequency generator 31 , with processor 21 with DAC, represented by dotted line block 102 enables output lines 33 and 37 to be combined to produce a single signal. The combination furthermore enables arbitrary or periodic wave forms of any shape to be generated, as similarly described in EP 0 592 851 B1.
  • AM modulator and power generator 34 produces an amplitude modulated carrier signal on modulated carrier signal line 38 , which is then applied to emitter output filter circuit 39 .
  • the filter circuit 39 is connected to probe or applicator 13 via power emission sensor 54 , coaxial cable 12 and impedance transformer 14 .
  • Microprocessor 21 controls DDS modulation signal generator circuit 31 of controllable generator circuit 29 via interface lines 25 .
  • microprocessor 21 may select a desired waveform stored in a modulation waveform storage device 43 and also controls a waveform address generator 41 to produce on waveform address bus 42 a sequence of addresses which are applied to modulation signal storage device 43 in order to retrieve the selected modulation signal.
  • the desired modulation signal is retrieved from modulation signal storage device 43 and applied to modulation signal bus 44 in digital form.
  • Modulation signal bus 44 is applied to wave form generator and DAC 46 which converts the digital modulation signal into analogue form.
  • This analogue modulation signal is then applied to a selective filter 47 which, under control of microprocessor 21 , filters the analogue modulation signal by use of a variable filter network including resistor 48 and capacitors 49 and 51 in order to smooth the wave form produced by DAC 46 on modulation signal line 20 .
  • a further embodiment possibility is a combination of PROCESSOR WITH DAC dotted line block 102 with OSCILLATOR dotted line block 104 or with a combination of oscillators 26 and 26 A.
  • the hardware solution described in EP 0 592 851 B1 can be realized internally in the processor 102 with multiple outputs 33 and 37 or a single output combining these signals.
  • the particular modulation control information employed by microprocessor 21 to control the operation of controllable generator circuit 29 is stored in application storage device 52 .
  • the application storage device is conveniently a computer comprising or being for receiving the information.
  • application storage devices illustrated and described in EP 0 592 851 B1, with reference to FIGS. 12, 13, 14 and 15, may be selected.
  • Interface 16 is configured as appropriate for the particular application storage device 52 in use. Interface 16 translates the control information stored in application storage device 52 into a usable form for storage within the memory of microprocessor 21 to enable microprocessor 21 to control controllable generator circuit 29 to produce the desired modulated low energy emission.
  • Interface 16 may directly read the information stored on application storage device 52 , or it may read the information through use of various known communication links. For example, radio frequency, microwave, laser, telephone, internet or optical based communications links may be employed to transfer information between interface or receiver 16 and application storage device or computer 52 .
  • the system 11 may comprise a user identification device, included in block 21 a in FIG. 2 . Conveniently, such a device communicates with the one or more data processors or integrated circuits 21 via interface 16 , as shown.
  • the user identification device may be of any type, a finger print reader being an example. Such a reader is for example available from Lenovo, 70563 Stuttgart, Germany, Part No. 73P4774.
  • control information stored in application storage device or computer 52 specifies various controllable parameters of the modulated low energy RF electromagnetic emission to be applied to a subject through applicator or probe 13 .
  • controllable parameters include, for example, but are not necessarily limited to, the frequency and amplitude of the carrier, the amplitudes and frequencies and wave forms of the modulation of the carrier, the duration of the emission, the power level of the emission, the duty cycle of the emission (i.e., the ratio of on time to off time of pulsed emissions applied during a treatment), the sequence of application of different modulation frequencies for a particular application, and the total number of treatments and duration of each treatment prescribed for a particular subject, and combinations thereof.
  • the carrier signal and modulation signal may be selected to drive the applicator or probe 13 with an amplitude modulated signal in which the carrier signal includes spectral frequency components below about 1 GHz, and preferably between about 1 MHz and about 900 MHz, and in which the modulation signal comprises spectral frequency components between about 0.01 Hz and 150 KHz.
  • the one or more modulation frequencies may be simultaneously emitted or sequenced to form the modulation signal.
  • an electromagnetic emission sensor 53 may be provided to detect the presence of electromagnetic emissions at the frequency of the carrier oscillator 32 .
  • Emission sensor 53 provides microprocessor 21 with an indication of whether or not electromagnetic emissions at the desired frequency are present.
  • Microprocessor 21 then takes appropriate action, for example, by displaying an error message on display 17 , disabling controllable generator circuit 29 , or the like.
  • a power sensor 54 is preferably included which detects the amount of power applied to the subject through applicator or probe 13 compared to the amount of power returned or reflected from the subject. This ratio is indicative of the proper use of the system during a therapeutic session. Power sensor 54 applies to microprocessor 21 , through power sensor line 56 , an indication of the amount of power applied to patient through applicator or probe 13 relative to the amount of power reflected from the patient.
  • the indication provided on power sense line 56 may be digitalized and employed by microprocessor 21 , for example, to detect and control a level of applied power, and to record on application storage device 52 information related to the actual treatments applied to and received by the patient. Such information may then be used by a physician or other clinician to assess patient treatment compliance and effect.
  • treatment information may include, for example: the number of treatments applied for a given time period; the actual time and date of each treatment; the number of attempted treatments; the treatment compliance (i.e., whether the applicator or probe was in place or not during the treatment session); and the cumulative dose of a particular modulation frequency.
  • the level of power applied is preferably controlled to cause the specific absorption rate (SAR) of energy absorbed by the patient to be from about 1 microWatt per kilogram of tissue to about 50 Watts per kilogram of tissue.
  • the power level is controlled to cause an SAR of from about 100 microWatts per kilogram of tissue to about 10 Watts per kilogram of tissue.
  • the power level is controlled to cause an SAR of from about 1 milliWatt per kilogram of tissue to about 100 milliWatts per kilogram of tissue.
  • SARs may be in any tissue of the patient, but are preferably in the tissue of the central nervous system or the diseased tissue.
  • System 11 may also include powering circuitry including battery and charger circuit 57 and battery voltage change detector 58 .
  • the RF carrier oscillator 32 produces a RF carrier frequency of about 27 MHz.
  • Other embodiments of the invention contemplate RF carrier frequencies of about 48 MHz, about 433 MHz or about 900 MHz.
  • the RF carrier frequency produced by carrier oscillator 32 has spectral frequency components less than about 1 GHz and preferably between about 1 MHz and about 916 MHz.
  • the carrier frequency produced by carrier oscillator 32 may be variable and controllable by microprocessor 21 by use of stored or transmitted control information.
  • Carrier oscillator 32 produces on carrier signal line 36 a carrier signal which is then modulated by the modulation signal carried on signal line 37 .
  • Oscillator disable line 33 enables microprocessor 21 to disable the signal from oscillator 32 by applying an appropriate disable signal to oscillator disable line 33 .
  • the output of the AM modulator and power generator 34 appears on signal line 38 .
  • This modulated signal is applied through emitter output filter 39 which substantially reduces or eliminates the carrier harmonics resulting from side effects of the modulator and power generator circuit 34 .
  • the output of the AM modulator and power generator 34 and emitter output filter 39 may be designed to possess a 50 Ohm output impedance to match a 50 Ohm impedance of coaxial cable 12 .
  • Impedance transformer 14 serves to match this complex impedance with the 50 Ohm impedance of coaxial cable 12 and therefore the output impedance of the AM modulator 34 and output filter 39 . This promotes power transmission, and minimizes reflections.
  • a contact probe with coupling to the mucosa of the mouth has been optimized for a contact probe with coupling to the mucosa of the mouth.
  • a conductive, isolated probe has been used at a frequency around 433 MHz coupling to the outer ear channel. Due to the different probe design in such a frequency band and with this coupling method, the values of matching elements ( 79 and 81 described in EP 0 592 851 B1) would be different or could even be omitted.
  • Applicator or probe 13 may then be regarded as a capacitive coupler or as an antenna matched to the capacitive load.
  • microprocessor 21 may operate to analyze the signal appearing on power sense line 56 to determine and control the amount of power applied to the patient, and to assess patient treatment compliance, and possibly to record indicia of the patient treatment compliance on application storage device 52 for later analysis and assessment by a physician or other clinician.
  • Exemplary of treatments performed on patients have included brain, bladder, colorectal, kidney, mesothelium, neuroendocrine, liver, lung, breast, ovary, pancreas, prostate and thyroid tumor types.
  • the treatments involved applying an about 27.12 MHz RF signal, amplitude modulated at specifically defined frequencies ranging from about 0.2 to about 23,000 Hz at very high precision and stability. Further Examples of treatment modes (at specific accurately controlled AM frequencies) for specified types of tumors are described in detail below.
  • a portable and programmable device capable of delivering low levels of amplitude-modulated electromagnetic fields has been developed.
  • the device emits a 27.12 MHz radiofrequency signal, amplitude-modulated at cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision.
  • the device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.
  • a phase I study was conducted consisting of three daily 40 min treatments. From March 2004 to September 2006, 24 patients with advanced solid tumors were enrolled. The median age was 57.0 ⁇ 12.2 years. 16 patients were female. As of January 2007, 5 patients are still on therapy, 13 patients died of tumor progression, 2 patients are lost to follow-up and one patient withdrew consent. The most common tumor types were breast ( 7 ), ovary ( 5 ) and pancreas ( 3 ). 22 patients had received prior systemic therapy and 16 had documented tumor progression prior to study entry.
  • the median duration of therapy was 15.7 ⁇ 19.9 weeks (range: 0.4-72.0 weeks). There were no NCI grade 2, 3 or 4 toxicities. Three patients experienced grade 1 fatigue during and immediately after treatment. 12 patients reported severe pain prior to study entry. Two of them reported significant pain relief with the treatment. Objective response could be assessed in 13 patients, 6 of whom also had elevated tumor markers. 6 additional patients could only be assessed by tumor markers.
  • patients with progressive disease at study entry one had a partial response for >14.4 weeks associated with >50% decrease in CEA, CA 125 and CA 15-3 (previously untreated metastatic breast cancer); one patient had stable disease for 34.6 weeks (add info); one patient had a 50% decrease in CA 19-9 for 12.4 weeks (recurrent pancreatic cancer).
  • the treatment is a safe and promising novel treatment modality for advanced cancer.
  • a phase II study and molecular studies are ongoing to confirm those results.
  • Phase I data suggest that low levels of electromagnetic fields amplitude-modulated at specific frequencies administered intrabucally with the device of Example A are a safe and potentially effective treatment for advanced cancer.
  • the device emits a 27.12 MHz RF signal, amplitude-modulated with cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision.
  • the device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced hepatocellular carcinoma HCC and limited therapeutic options were offered treatment with a combination of HCC-specific frequencies.
  • the electronic device of the present invention comprising means for the accurate control over the frequencies and stability of amplitude modulations of a high frequency carrier signal, provides a safe and promising novel treatment modality for the treatment of patients suffering from various types of advanced forms of cancer.
  • Exemplary of above accurately controlled amplitude modulated frequencies controlling the frequency of amplitude modulations of a high frequency carrier signal are set forth below along with the type of cancer or tumor harbored by a subject to be treated.
  • the above Examples reflect AM frequencies determined by a bio-feedback procedure involving very substantial observations and measurements of physiological responses (at certain well defined AM frequencies) by subjects exposed to low energy electromagnetic emission excitation. In general, it is recommended that all of the listed frequencies be applied in the treatment of subjects suffering from the indicated form of cancer. However, a limited number of the listed frequencies also lead to beneficial effects.
  • the electronic system of the present invention may be adapted to screen a subject for physiological responses over a broad range of frequencies to determine the presence or absence tumor cells and, if positive, then to note at which defined frequencies physiological responses are elicited. These frequencies will in general match with the defined frequencies listed in one or other of the Examples above or such further examples as may be developed and hence the nature of the tumor will be known.
  • the electronic system of the invention is therefore a valuable diagnostic tool for diagnosing the presence or absence and identities of types of tumor cell growths or cancers. Furthermore, the electronic system of the invention is of value for predicting whether a patient will benefit from the application of a given series of modulation frequencies. The system therefore possesses a capability of predicting responses to treatment, thereby enhancing the possibility to select optimal modes. of treatment.
  • the sequence of well defined frequencies are preferably applied sequentially for determined periods of time, e.g., 3 seconds for each frequency, but several frequencies may also be applied simultaneously. This means that a cycle of application involving 180 frequencies would take nearly 10 minutes time. Advantageous effects may however also arise from applying individual well defined frequencies for differing time periods, e.g., some for 3 seconds, some for 6 seconds, etc.
  • Therapeutic dosages to be applied to a subject suffering from the presence of tumor cell growth or cancer are determined by the time of application of the low energy electromagnetic emissions to the subject and will depend on the nature of the cancer and the overall condition of the subject. In general, however, greatest experience has been gained in treating terminally ill subjects expected to survive no longer than about three months and who have agreed to discontinue alternative forms of cancer treatments such as chemo-therapy or radioactive treatment. In these severe cases, lengthy times of treatment are recommended, e.g., 3 times 1 hour daily treatment.
  • alternative forms of application i.e., other than by means of a mouth probe, continuous application is possible and is likely to enhance compliance and the efficacy of the treatment.

Abstract

An electronic system activatable by electrical power is described. The system is useful for influencing cellular functions or malfunctions in a warm-blooded mammalian subject. The system includes one or more controllable low energy HF (High Frequency) carrier signal generator circuits, one or more data processors for receiving control information, one or more amplitude modulation control generators and one or more amplitude modulation frequency control generators. The amplitude modulation frequency control generators are adapted to accurately control the frequency of the amplitude modulations to within an accuracy of at least 1000 ppm, most preferably to within about 1 ppm, relative to one or more determined or predetermined reference amplitude modulation frequencies.

Description

RELATED APPLICATION
This application claims the benefit of U.S. patent application Ser. No. 12/450,450 filed Sep. 25, 2009, of which the present application is a continuation-in-part.
FIELD OF INVENTION
This invention relates to an electronic system for influencing cellular functions in a warm-blooded mammalian subject. More particularly, the invention concerns research findings related to how earlier electronic systems may be modified and programmed to achieve both improved and additional therapeutic effects.
BACKGROUND OF INVENTION
Reference is made to European Patent EP 0 592 851 B1 and corresponding patents and patent applications and to the various publications referred to therein. Since the time of the priority application filed in the USA on 25 Sep. 1992 (U.S. Ser. No. 951,563 now U.S. Pat. No. 5,441,528), a number of further publications related to effects of very low energy electromagnetic fields on patients suffering from insomnia and/or anxiety disorders have taken place and are as follows:
  • Koziol, J. A., Erman, M., Pasche B., Hajdukovic R., Mitler, M. M., (1993), “Assessing a changepoint in a sequence of repeated measurements with application to a low-energy emission therapy sleep study”. J. Applied Statistics 20: 393-400;
  • Amato, D., Pasche, B., (1993), “An evaluation of the safety of low energy emission therapy”. Compr Ther 19: 242-247;
  • Higgs, L., Reite, M., Barbault, A., Lebet, J. P., Rossel, C., Amato, D., Dafni, U., Pasche. B., (1994), “Subjective and Objective Relaxation Effects of Low Energy Emission Therapy”. Stress Medicine 10: 5-13;
  • Reite, M., Higgs, L, Lebet, J. P., Barbault, A., Rossel, C., Kuster, N., Dafni, U., Amato, D., Pasche, B., (1994), “Sleep Inducing Effect of Low Energy Emission Therapy”. Bioelectromagnetics 15: 67-75.
  • Lebet, J. P., Barbault, A., Rossel, C., Tomic, Z., Reite, M., Higgs, L., Dafni, U., Amato, D., Pasche, B., (1996), “Electroencephalographic changes following low energy emission therapy”. Ann Biomed Eng 24: 424-429;
  • Pasche, B., Erman, M., Hayduk, R., Mitler, M., Reite, M., Higgs, L., Dafni, U., Amato, D., Rossel, C., Kuster, N., Barbault, A., Lebet, J. P., (1996), “Effects of Low Energy Emission Therapy in chronic psychophysiological insomnia”. Sleep 19: 327-336;
  • Kelly, T. L., Kripke, D. F., Hayduk, R., Ryman, D., Pasche, B., Barbault, A., (1997), “Bright light and LEET effects on circadian rhythms, sleep and cognitive performance”. Stress Medicine 13: 251-258; and
  • Pasche, B., Barbault, A., (2003), “Low-Energy Emission Therapy Current Status and Future Directions. In Bioelectromagnetic Medicine”, Rosch, P. J., Markov, M. S. (eds.), pages 321-327, Marcel Dekker, Inc.: New York, N.Y.
The above publications are related to an earlier device, system and use thereof described in said EP 0 592 851 B1. The improved electronic system and programmed control thereof in accordance with the present invention, however, has been determined to find therapeutic application not only for influencing cellular functions (or malfunctions) leading to central nervous system (CNS) disorders, but more particularly for influencing other cellular functions (or malfunctions) including directly or indirectly influencing cancerous cell growth or proliferation thereof in warm-blooded mammalian subjects. The direct or indirect influence on cancerous cell growth may involve but is not necessarily limited to any of prophylactic avoidance of cancerous cell formation, influencing of cell functions such as for example influencing leukocyte cell functions which can lead to inhibition of cancerous cell growth or proliferation thereof, and/or killing of cancerous cells harboured by a warm-blooded mammalian subject.
Electromagnetic energy generating devices and use of electromagnetic energies for treating living mammalian subjects harbouring cancerous cells described in the literature include: U.S. Pat. No. 5,908,441 issued Jun. 1, 1999 to James E. Bare and the references cited therein and so-called “NovoCure technology” involving in vivo implantation of electrodes to either side of tumorous growths. This literature, however, does not contemplate very low energy emissions of electromagnetic energy involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
U.S. Pat. No. 5,690,692 issued Nov. 25, 1997 entitled “Bio-Active Frequency Generator and Method” describes a programmable control which instructs a frequency synthesizer to enable generation of an electrical current at a specific precise frequency signal or at a series of specific precise frequency signals having a square wave form to within an accuracy of 0.001 Hz. This patent contemplates amplifying the voltage of the generated signals and applying the signals to a subject at the specific precise frequency or sequentially at the series of specific precise frequencies by means of electrodes held by or otherwise connected to the subject (which may be a mammal or a food). Once again, this patent does not contemplate very low energy emissions involving amplitude-modulated high frequency carrier signals as required in terms of the present invention.
SUMMARY OF THE INVENTION
In one aspect of the invention, an electronic system is provided which is activatable by electrical power. The system is employed to influence cellular functions or malfunctions in a warm-blooded mammalian subject. The system comprises one or more controllable low energy electromagnetic energy generator circuits for generating one or more high frequency radio frequency RF carrier signals. One or more microprocessors or integrated circuits comprising or communicating with the one or more generator circuits are provided which are also for receiving control information from a source of programmed control information. The one or more generator circuits include one or more amplitude modulation control signal generators for controlling amplitude modulated variations of the one or more high frequency carrier signals. The one or more generator circuits furthermore include one or more programmable amplitude modulation frequency control signal generators for controlling the frequency at which the amplitude modulations are generated. The one or more amplitude modulation frequency control generators are, in terms of an important improvement of the present invention, adapted to accurately control the frequency of the amplitude modulations to within an accuracy of at least 1000 parts per million (ppm) relative to one or more determined or predetermined reference amplitude modulation frequencies selected from within a range of 0.01 Hz to 150 kHz. The system furthermore comprises a connection or coupling position for connection or coupling to or being connected or coupled to an electrically conductive applicator for applying to the warm-blooded mammalian subject the one or more amplitude-modulated low energy emissions at said accurately controlled modulation frequencies.
As used herein, the term, “accurately controlled” means that the modulated low energy electromagnetic emissions should be modulated to within a resolution of at most about 1 Hz of intended higher frequencies (greater than about 1000 Hz) determined or predetermined modulation frequencies. For example, if one of the one or more determined or predetermined modulation frequencies to be applied to the warm-blooded mammalian subject is about 2000 Hz, the accurate control should lead to such modulated low energy emission being generated at a frequency of between about 1999 and about 2001 Hz. However, and in terms of what has been determined from experiences in treating human subjects harbouring cancerous cells with the aim of arresting proliferation or killing of such cells, it is preferable that the accurate control should lead to a resolution of about 0.5, more preferably about 0.1, yet more preferably about 0.01 and indeed most preferably about 0.001 Hz of the intended determined or predetermined modulation frequency.
Of importance is the requirement for emissions to be at a very low and safe energy level and result in low levels of absorption, the reason believed to be that physiological exchanges or flow of electrical impulses within warm-blooded animals (which are to be affected by application of the emissions of the present invention) are similarly at very low energy levels. In any event, in the region (at or near to the position of contact or close-by induction of the electrically conductive applicator with a subject receiving treatment), the specific absorption rate (SAR) should be and is most preferably substantially less than 1.6 milliW/g weight of living tissue.
Furthermore of importance to achieve the intended biological therapeutic effect is that the stability of the emissions be maintained during emission, and that such stability should preferably be of the order of 10−5, more preferably 10−6, and most preferably 10−7, stability being determined as the relative deviation of frequency divided by the desired frequency, e.g., 0.01 Hz (deviation)/1,000 Hz (desired freq.)=10−5.
As already described in said EP 0 592 851 B1, the system includes a microprocessor (which may more recently be replaced by an integrated circuit) into which control information is loaded from an application storage device. The microprocessor (or now alternatively integrated circuit) then controls the function of the system to produce the desired therapeutic emissions. Also described is the provision in the system of an impedance transformer connected intermediate the emitter of low energy electromagnetic emissions and a probe (here more broadly described as an electrically conductive applicator) for applying the emissions to the patient. The impedance transformer substantially matches the impedance of the patient seen from the emitter circuit with the impedance of the output of the emitter circuit.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows an exemplary casing structure for the electronic circuit shown in FIG. 2, an applicator 13 (exemplified as a probe suitable for being placed in the mouth of a patient) and an interface 16 (which may be replaced by a receiver) for receiving information from a source of information 52 such as may be comprised in an information storage device, e.g., of the nature described and illustrated in FIGS. 12 to 17 of EP 0 592 851 B1.
FIG. 2 is a block diagram of exemplary circuitry which may be comprised in the exemplary casing structure of FIG. 1. This FIG. 2 differs essentially from FIG. 2 of EP 0 592 851 B1 by comprising a highly accurate modulation frequency generator 31 (named a Digital Direct Synthesizer or DDS), which enables accurate control of modulatable oscillator represented by dotted line block 106.
Reference is made to the various Figures of EP 0 592 851 B1 and the detailed description thereof, a number of which are exemplary of components which may be comprised in the circuit of FIG. 2.
Thus, FIG. 3 of EP 0 592 851 B1 is a detailed schematic of a modulation signal generator 31, replaced by a DDS modulation frequency generator 31 comprised in the circuit of present FIG. 2.
FIG. 4 of EP 0 592 851 B1 is a detailed schematic of a modulation signal buffer and carrier oscillator circuit which may be employed in the circuit of the present FIG. 2.
FIG. 5 of EP 0 592 851 B1 is a detailed schematic example of an amplitude modulation (AM) and power generator 34 and output filter 39 which could be comprised in the circuit of the present FIG. 2.
FIG. 6 of EP 0 592 851 B1 is a detailed schematic example of an impedance transformer 14 which may be comprised in the circuit of the present FIG. 2.
FIG. 7 of EP 0 592 851 B1 is a detailed schematic example of an emission sensor 53 which may be comprised in the circuit of the present FIG. 2.
FIG. 8 of EP 0 592 851 B1 is a detailed schematic example of an output power sensor circuit 54 which may be employed in the circuit of the present FIG. 2.
FIG. 9 of EP 0 592 851 B1 is a detailed schematic example of a display module or information output 17 which may be included in the circuit of the present FIG. 2.
FIG. 10 of EP 0 592 851 B1 is a detailed schematic example of a power supply control circuit including battery charger 57 which may be comprised in the circuit of the present FIG. 2.
FIGS. 11 a-d of EP 0 592 851 B1 are exemplary flow charts of the method of operation of the system of FIGS. 1 and 2.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Referring to FIG. 1, presented is a modulated low energy electromagnetic emission application system 11, in accordance with the present invention. As described in prior U.S. Pat. Nos. 4,649,935 and 4,765,322, such a system has proven to be useful in the practice of Low Energy Emission Therapy (LEET, a trademark of Symtonic S.A. or a successor of this Company), which involves application of emissions of low energy radio frequency (RF) electromagnetic waves to a warm-blooded mammalian subject. The application has proven to be an effective mode of treating a warm-blooded mammalian subject suffering from central nervous system (CNS) disorders such as, for example, generalized anxiety disorders, panic disorders, sleep disorders including insomnia, psychiatric disorders such as depression, obsessive compulsive disorders, disorders resulting from substance abuse, sociopathy, post traumatic stress disorders or other disorders of the central nervous system and combinations thereof.
The system includes an electrically conductive applicator 12, 13 for applying one or more electromagnetic emissions to the warm-blooded mammalian subject. One form of applicator may consist of an electrically conductive probe or mouthpiece 13 which is inserted into the mouth of a subject undergoing treatment. Probe 13 is connected to an electromagnetic energy emitter (see also FIG. 2), through coaxial cable 12 and impedance matching transformer 14.
It has previously been considered that an efficient connection of an electrically conductive applicator to a subject could only be achieved by means of a probe which is adapted to be applied to any mucosa of the subject, such as by being located within oral, nasal, optical, urethral, anal, and/or vaginal cavities or surfaces. It has, however, now been determined that in fact satisfactory application of emissions to a patient can be achieved by simpler physical contact of the electrically conductive applicator with the skin of the patient. Emissions to the patient may, for example be achieved by a conductive, inductive, capacitive or radiated coupling to the patient. An example of a coupling found to be effective involving indirect physical contact with the skin of a patient, is an insulated applicator to be placed over or within an ear of the patient. The emissions thus passed to the patient may be either by capacitive or radiated means or by a combination of both. An important advantage of a device which does not need to be placed in the mouth of a patient is that the patient is able to speak clearly during a time of treatment and can receive treatment during activities of daily living. The treatment is accordingly more user-friendly, can be administered for longer periods of time and can lead to enhanced patient compliance.
Electronic system 11 also includes a connector or coupler for connection to a programmable device such as a computer or an interface or receiver 16 which is adapted to receive an application storage device 52 such as, for example, magnetic media, semiconductor media, optical media or mechanically encoded media, or programmed emissions programmed with control information employed to control the operation of system 11 so that the desired type of low energy emission therapy is applied to the patient.
Application storage device 52 can be provided with a microprocessor which, when applied to interface 16, operates to control the function of system 11 to apply the desired low energy emission therapy. Alternatively, application storage device 52 can be provided with a microprocessor which is used in combination with microprocessor 21 within system 11. In such case, the microprocessor within device 52 could assist in the interfacing of storage device 52 with system 11, or could provide security checking functions.
System 11 may also include a display 17 which can display various indications of the operation of system 11. In addition, system 11 may include on and off power buttons 18 and 19, optionally replaced by user interface 21A (refer to FIG. 2).
Referring to FIG. 2, presented is a block diagram of exemplary electronic circuitry of system 11, in accordance with the present invention. A data processor, such as for example, microprocessor or integrated circuit 21, operates as the controller for electronic system 11, and is connected to control the various components of the system 11, for example, through address bus 22, data bus 23 and input/output lines 25. The block diagram of FIG. 2 is modified as compared to FIG. 2 of EP 0 592 851 B1 by including what is known as a digital direct synthesizer (DDS) 31 which operates as an accurate and stable modulation frequency generator within the system 11. An exemplary DDS device is available from Analog Devices of Norwood, Mass. 02062-9106, USA, Part No. AD9835. The device is a numerically controlled oscillator and modulation capabilities are provided for phase modulation and frequency modulation. As represented by dotted line block 102, entitled “PROCESSOR WITH DAC”, the functionality of the DDS may also be combined with microprocessor 21 with digital to analogue converter (DAC).
Microprocessor 21 preferably includes internal storage for the operation of a coded control program, and temporary data. In addition, microprocessor 21 may include input/output ports and internal timers. Microprocessor 21 may be a microcontroller, for example microcontrollers 8048 or 8051 available from Intel Corporation of Santa Clara, Calif. 95054-1549, USA.
The timing for microprocessor 21 is provided by system clock oscillator 26A which may be run at any clock frequency suitable for the particular type of microprocessor used. An exemplary clock frequency is about 8.0 MHz. Oscillator 26A may be replaced by reference frequency oscillator 26 which secures the stability of the accurate modulation frequency. RF (radio frequency) oscillator 32 may also be employed for this purpose. A combination of oscillators is represented by dotted line block 104, entitled “OSCILLATOR”.
An exemplary operating program for microprocessor 21 is presented in flow chart form with reference to FIGS. 11 a-d of EP 0 592 851 B1. In general, microprocessor 21 functions to control controllable electromagnetic energy generator circuit 29 to produce a desired form of modulated low energy electromagnetic emission for application to a subject through applicator or probe 13.
Dotted line block 29, entitled CONTROLLABLE GENERATOR, includes DDS modulation frequency generator 31 and carrier signal oscillator 32. Microprocessor 21 operates to activate or de-activate controllable generator circuit 29 through oscillator disable line 33, as described in greater detail in EP 0 592 851 B1. Controllable generator circuit 29 also includes an AM modulator and power generator 34 which operates to amplitude modulate a carrier signal produced by carrier oscillator 32 on carrier signal line 36, with a modulation signal produced by modulation signal generator circuit 31 on modulation signal line 37. The combination of the functionality of the DDS modulation frequency generator 31, with processor 21 with DAC, represented by dotted line block 102, enables output lines 33 and 37 to be combined to produce a single signal. The combination furthermore enables arbitrary or periodic wave forms of any shape to be generated, as similarly described in EP 0 592 851 B1.
AM modulator and power generator 34 produces an amplitude modulated carrier signal on modulated carrier signal line 38, which is then applied to emitter output filter circuit 39. The filter circuit 39 is connected to probe or applicator 13 via power emission sensor 54, coaxial cable 12 and impedance transformer 14.
Microprocessor 21 controls DDS modulation signal generator circuit 31 of controllable generator circuit 29 via interface lines 25.
As is illustrated and described in EP 0 592 851 B1, microprocessor 21 may select a desired waveform stored in a modulation waveform storage device 43 and also controls a waveform address generator 41 to produce on waveform address bus 42 a sequence of addresses which are applied to modulation signal storage device 43 in order to retrieve the selected modulation signal. In the embodiment described in EP 0 592 851 B1, the desired modulation signal is retrieved from modulation signal storage device 43 and applied to modulation signal bus 44 in digital form. Modulation signal bus 44 is applied to wave form generator and DAC 46 which converts the digital modulation signal into analogue form. This analogue modulation signal is then applied to a selective filter 47 which, under control of microprocessor 21, filters the analogue modulation signal by use of a variable filter network including resistor 48 and capacitors 49 and 51 in order to smooth the wave form produced by DAC 46 on modulation signal line 20.
A further embodiment possibility is a combination of PROCESSOR WITH DAC dotted line block 102 with OSCILLATOR dotted line block 104 or with a combination of oscillators 26 and 26A. With such a combination, the hardware solution described in EP 0 592 851 B1 can be realized internally in the processor 102 with multiple outputs 33 and 37 or a single output combining these signals.
The above embodiment from EP 0 592 851 B1 is in part replaced by the functionality of the DDS modulation frequency modulator 31. However, if it is determined that emissions of different wave forms is, desirable, it would be desirable to include the modulation signal storage device 43 and wave form generator 46 described in EP 0 592 851 B1. Various modulation signal wave forms may then be stored in modulation signal storage device 43. Wave forms that have been successfully employed include square wave forms or sinusoidal wave forms. Other possible modulation signal wave forms include rectified sinusoidal, triangular, or other wave forms and combinations of all of the above.
The particular modulation control information employed by microprocessor 21 to control the operation of controllable generator circuit 29, is stored in application storage device 52. The application storage device is conveniently a computer comprising or being for receiving the information. Alternatively, application storage devices illustrated and described in EP 0 592 851 B1, with reference to FIGS. 12, 13, 14 and 15, may be selected.
Interface 16 is configured as appropriate for the particular application storage device 52 in use. Interface 16 translates the control information stored in application storage device 52 into a usable form for storage within the memory of microprocessor 21 to enable microprocessor 21 to control controllable generator circuit 29 to produce the desired modulated low energy emission.
Interface 16 may directly read the information stored on application storage device 52, or it may read the information through use of various known communication links. For example, radio frequency, microwave, laser, telephone, internet or optical based communications links may be employed to transfer information between interface or receiver 16 and application storage device or computer 52.
The system 11 may comprise a user identification device, included in block 21 a in FIG. 2. Conveniently, such a device communicates with the one or more data processors or integrated circuits 21 via interface 16, as shown. The user identification device may be of any type, a finger print reader being an example. Such a reader is for example available from Lenovo, 70563 Stuttgart, Germany, Part No. 73P4774.
The control information stored in application storage device or computer 52 specifies various controllable parameters of the modulated low energy RF electromagnetic emission to be applied to a subject through applicator or probe 13. Such controllable parameters include, for example, but are not necessarily limited to, the frequency and amplitude of the carrier, the amplitudes and frequencies and wave forms of the modulation of the carrier, the duration of the emission, the power level of the emission, the duty cycle of the emission (i.e., the ratio of on time to off time of pulsed emissions applied during a treatment), the sequence of application of different modulation frequencies for a particular application, and the total number of treatments and duration of each treatment prescribed for a particular subject, and combinations thereof.
For example, the carrier signal and modulation signal may be selected to drive the applicator or probe 13 with an amplitude modulated signal in which the carrier signal includes spectral frequency components below about 1 GHz, and preferably between about 1 MHz and about 900 MHz, and in which the modulation signal comprises spectral frequency components between about 0.01 Hz and 150 KHz. The one or more modulation frequencies may be simultaneously emitted or sequenced to form the modulation signal.
As an additional feature, an electromagnetic emission sensor 53 may be provided to detect the presence of electromagnetic emissions at the frequency of the carrier oscillator 32. Emission sensor 53 provides microprocessor 21 with an indication of whether or not electromagnetic emissions at the desired frequency are present. Microprocessor 21 then takes appropriate action, for example, by displaying an error message on display 17, disabling controllable generator circuit 29, or the like.
A power sensor 54 is preferably included which detects the amount of power applied to the subject through applicator or probe 13 compared to the amount of power returned or reflected from the subject. This ratio is indicative of the proper use of the system during a therapeutic session. Power sensor 54 applies to microprocessor 21, through power sensor line 56, an indication of the amount of power applied to patient through applicator or probe 13 relative to the amount of power reflected from the patient.
The indication provided on power sense line 56 may be digitalized and employed by microprocessor 21, for example, to detect and control a level of applied power, and to record on application storage device 52 information related to the actual treatments applied to and received by the patient. Such information may then be used by a physician or other clinician to assess patient treatment compliance and effect. Such treatment information may include, for example: the number of treatments applied for a given time period; the actual time and date of each treatment; the number of attempted treatments; the treatment compliance (i.e., whether the applicator or probe was in place or not during the treatment session); and the cumulative dose of a particular modulation frequency.
The level of power applied is preferably controlled to cause the specific absorption rate (SAR) of energy absorbed by the patient to be from about 1 microWatt per kilogram of tissue to about 50 Watts per kilogram of tissue. Preferably, the power level is controlled to cause an SAR of from about 100 microWatts per kilogram of tissue to about 10 Watts per kilogram of tissue. Most preferably, the power level is controlled to cause an SAR of from about 1 milliWatt per kilogram of tissue to about 100 milliWatts per kilogram of tissue. These SARs may be in any tissue of the patient, but are preferably in the tissue of the central nervous system or the diseased tissue.
System 11 may also include powering circuitry including battery and charger circuit 57 and battery voltage change detector 58.
The RF carrier oscillator 32 produces a RF carrier frequency of about 27 MHz. Other embodiments of the invention contemplate RF carrier frequencies of about 48 MHz, about 433 MHz or about 900 MHz. In general, the RF carrier frequency produced by carrier oscillator 32 has spectral frequency components less than about 1 GHz and preferably between about 1 MHz and about 916 MHz. Although the described embodiment contemplates that once set, the carrier oscillator frequency remains substantially constant, the carrier frequency produced by carrier oscillator 32 may be variable and controllable by microprocessor 21 by use of stored or transmitted control information.
Carrier oscillator 32 produces on carrier signal line 36 a carrier signal which is then modulated by the modulation signal carried on signal line 37.
Oscillator disable line 33 enables microprocessor 21 to disable the signal from oscillator 32 by applying an appropriate disable signal to oscillator disable line 33.
The output of the AM modulator and power generator 34 appears on signal line 38. This modulated signal is applied through emitter output filter 39 which substantially reduces or eliminates the carrier harmonics resulting from side effects of the modulator and power generator circuit 34.
The output of the AM modulator and power generator 34 and emitter output filter 39 may be designed to possess a 50 Ohm output impedance to match a 50 Ohm impedance of coaxial cable 12.
It has been determined through impedance measurements that when a probe 13 is applied within the mouth of a subject, the probe/subject combination exhibits a complex impedance of the order of about 150+j200 Ohms. Impedance transformer 14 serves to match this complex impedance with the 50 Ohm impedance of coaxial cable 12 and therefore the output impedance of the AM modulator 34 and output filter 39. This promotes power transmission, and minimizes reflections.
The arrangement described above has been optimized for a contact probe with coupling to the mucosa of the mouth. In a further example, a conductive, isolated probe has been used at a frequency around 433 MHz coupling to the outer ear channel. Due to the different probe design in such a frequency band and with this coupling method, the values of matching elements (79 and 81 described in EP 0 592 851 B1) would be different or could even be omitted. Applicator or probe 13 may then be regarded as a capacitive coupler or as an antenna matched to the capacitive load.
As described in EP 0 592 851 B1, with reference to the flow charts of FIGS. 11 a-d, microprocessor 21 may operate to analyze the signal appearing on power sense line 56 to determine and control the amount of power applied to the patient, and to assess patient treatment compliance, and possibly to record indicia of the patient treatment compliance on application storage device 52 for later analysis and assessment by a physician or other clinician.
Exemplary of treatments performed on patients have included brain, bladder, colorectal, kidney, mesothelium, neuroendocrine, liver, lung, breast, ovary, pancreas, prostate and thyroid tumor types. The treatments involved applying an about 27.12 MHz RF signal, amplitude modulated at specifically defined frequencies ranging from about 0.2 to about 23,000 Hz at very high precision and stability. Further Examples of treatment modes (at specific accurately controlled AM frequencies) for specified types of tumors are described in detail below.
The following are synopses of abstracts for future publications related to uses of electronic devices of the present invention:
Example A
A Phase I Study of Therapeutic Amplitude-Modulated Electromagnetic Fields (THERABIONIC) in Advanced Tumors
  • Boris Pasche 1, Alexandre Barbault 1, Brad Bottger 2, Fin Bomholt 3, Niels Kuster 4.
  • 1 Cabinet Médical de l'Avenue de la Gare 6, CH-1003-Lausanne, Switzerland.
  • 2 Danbury Hospital, Danbury, CT-06810.
  • 3 SPEAG, Zurich, CH-8004-Zurich, Switzerland.
  • 4 IT′IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland.
Background:
In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. Specific frequencies have been identified specific frequencies that may block cancer cell growth. A portable and programmable device capable of delivering low levels of amplitude-modulated electromagnetic fields has been developed. The device emits a 27.12 MHz radiofrequency signal, amplitude-modulated at cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.
Methods:
A phase I study was conducted consisting of three daily 40 min treatments. From March 2004 to September 2006, 24 patients with advanced solid tumors were enrolled. The median age was 57.0±12.2 years. 16 patients were female. As of January 2007, 5 patients are still on therapy, 13 patients died of tumor progression, 2 patients are lost to follow-up and one patient withdrew consent. The most common tumor types were breast (7), ovary (5) and pancreas (3). 22 patients had received prior systemic therapy and 16 had documented tumor progression prior to study entry.
Results:
The median duration of therapy was 15.7±19.9 weeks (range: 0.4-72.0 weeks). There were no NCI grade 2, 3 or 4 toxicities. Three patients experienced grade 1 fatigue during and immediately after treatment. 12 patients reported severe pain prior to study entry. Two of them reported significant pain relief with the treatment. Objective response could be assessed in 13 patients, 6 of whom also had elevated tumor markers. 6 additional patients could only be assessed by tumor markers. Among patients with progressive disease at study entry, one had a partial response for >14.4 weeks associated with >50% decrease in CEA, CA 125 and CA 15-3 (previously untreated metastatic breast cancer); one patient had stable disease for 34.6 weeks (add info); one patient had a 50% decrease in CA 19-9 for 12.4 weeks (recurrent pancreatic cancer). Among patients with stable disease at enrollment, four patients maintained stable disease for 17.0, >19.4, 30.4 and >63.4 weeks.
Conclusions:
The treatment is a safe and promising novel treatment modality for advanced cancer. A phase II study and molecular studies are ongoing to confirm those results.
Example B A Phase II Study of Therapeutic Amplitude-Modulated Electromagnetic Fields (THERABIONIC) in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
  • Frederico P Costa 1, Andre Cosme de Oliveira 1, Roberto Meirelles Jr 1, Rodrigo Surjan 1, Tatiana Zanesco1, Maria Cristina Chammas 1, Alexandre Barbault 2, Boris Pasche 2.
  • 1 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 2 Cabinet Médical Avenue de la Gare 6, CH-1003-Lausanne, Switzerland.
Background:
Phase I data suggest that low levels of electromagnetic fields amplitude-modulated at specific frequencies administered intrabucally with the device of Example A are a safe and potentially effective treatment for advanced cancer. The device emits a 27.12 MHz RF signal, amplitude-modulated with cancer-specific frequencies ranging from 0.2 to 23,000 Hz with high precision. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced hepatocellular carcinoma HCC and limited therapeutic options were offered treatment with a combination of HCC-specific frequencies.
Methods:
From October 2005 to October 2006, 38 patients with advanced HCC were recruited in a phase II study. The patients received three daily 40 min treatments until disease progression or death. The median age was 64.0±14.2 years. 32 patients were male and 29 patients had documented progression of disease (POD) prior to study entry.
Results:
As of January 2007, 12 patients are still on therapy, 20 patients died of tumor progression, 2 patients are lost to follow-up and 3 patients withdrew consent. 27 patients are eligible for response. The overall objective response rate as defined by partial response (PR) or stable disease (SD) in patients with documented POD at study entry was 31.6%: 3 PR and 9 SD. The median survival was 20.7 weeks with a median duration of therapy of 17.5 weeks. 13 patients have received therapy for more than six months. The median duration of response is 12.9 weeks. 12 patients reported pain at study entry: 8 of them (66%) experienced decreased pain during treatment. There were no NCI grade 2/3/4 toxicities. One patient developed grade 1 mucositis and grade 1 fatigue.
Patient characteristics (n = 38)
Cirrhosis 36
Portal vein thrombosis 9
Elevated AFP 25
Extra-hepatic metastases 12
Previous intrahepatic/systemic therapy 30
Previous hepatic resection/RFA or 8
ethanol
CLIP 0/1: 12 ≧2: 22
Okuda I: 14 II/III: 20
Child-Pugh A: 15 B: 19
MELD Median: 10
Conclusion:
In patients with advanced HCC the treatment is a safe and effective novel therapeutic option, which has antitumor effect and provides pain relief in the majority of patients.
Thus, it seen that the electronic device of the present invention, comprising means for the accurate control over the frequencies and stability of amplitude modulations of a high frequency carrier signal, provides a safe and promising novel treatment modality for the treatment of patients suffering from various types of advanced forms of cancer.
Exemplary of above accurately controlled amplitude modulated frequencies controlling the frequency of amplitude modulations of a high frequency carrier signal are set forth below along with the type of cancer or tumor harbored by a subject to be treated.
Example 1 AM Frequencies Employed for Treatment of Breast Cancer (232 Frequencies so Far Included)
78.76 Hz
181.821 Hz
331.3 Hz
414.817 Hz
430.439 Hz
440.933 Hz
618.8 Hz
628.431 Hz
655.435 Hz
677.972 Hz
721.313 Hz
752.933 Hz
813.205 Hz
818.342 Hz
825.145 Hz
839.521 Hz
841.211 Hz
843.312 Hz
891.901 Hz
929.095 Hz
929.1 Hz
929.131 Hz
958.929 Hz
1021 Hz
1021.311 Hz
1156.79 Hz
1372.207 Hz
1372.934 Hz
1555.282 Hz
1588.721 Hz
1624.802 Hz
1670.699 Hz
1821.729 Hz
1836.219 Hz
2193.937 Hz
2221.323 Hz
2278.312 Hz
2332.949 Hz
2357.832 Hz
2381.443 Hz
2417.323 Hz
2423.292 Hz
2431.334 Hz
2450.332 Hz
2551.313 Hz
2556.221 Hz
2598.853 Hz
2621.322 Hz
2740.191 Hz
2823.428 Hz
2831.386 Hz
2851.347 Hz
2885.322 Hz
2919.273 Hz
3074.333 Hz
3115.188 Hz
3239.212 Hz
3249.529 Hz
3405.182 Hz
3432.274 Hz
3434.693 Hz
3594.231 Hz
3647.619 Hz
3657.931 Hz
3742.957 Hz
3753.382 Hz
3830.732 Hz
3855.823 Hz
3916.321 Hz
3935.218 Hz
3975.383 Hz
3993.437 Hz
4153.192 Hz
4194.968 Hz
4241.321 Hz
4243.393 Hz
4253.432 Hz
4314.444 Hz
4318.222 Hz
4375.962 Hz
4393.419 Hz
4394.134 Hz
4417.243 Hz
4481.463 Hz
4482.223 Hz
4495.138 Hz
4549.808 Hz
4558.306 Hz
4751.908 Hz
4779.451 Hz
4838.674 Hz
4871.513 Hz
4878.687 Hz
4895.296 Hz
4962.213 Hz
4969.224 Hz
4979.321 Hz
5027.231 Hz
5059.792 Hz
5118.094 Hz
5176.287 Hz
5365.222 Hz
5376.392 Hz
5426.323 Hz
5431.542 Hz
5521.621 Hz
5536.242 Hz
5739.422 Hz
5745.218 Hz
5821.975 Hz
6037.432 Hz
6044.333 Hz
6086.256 Hz
6208.932 Hz
6212.808 Hz
6231.031 Hz
6280.321 Hz
6329.391 Hz
6476.896 Hz
6477.098 Hz
6497.319 Hz
6504.983 Hz
6651.276 Hz
6657.913 Hz
6757.901 Hz
6758.321 Hz
6855.286 Hz
6858.121 Hz
6898.489 Hz
6915.886 Hz
7092.219 Hz
7120.218 Hz
7127.311 Hz
7156.489 Hz
7208.821 Hz
7224.197 Hz
7282.169 Hz
7285.693 Hz
7376.329 Hz
7488.742 Hz
7541.319 Hz
7577.421 Hz
7621.085 Hz
7627.207 Hz
7650.939 Hz
7668.231 Hz
7691.212 Hz
7842.184 Hz
7849.231 Hz
7915.423 Hz
7932.482 Hz
7949.196 Hz
7967.311 Hz
8021.229 Hz
8070.181 Hz
8114.032 Hz
8149.922 Hz
8194.19 Hz
8245.801 Hz
8328.322 Hz
8330.534 Hz
8355.987 Hz
8408.121 Hz
8431.184 Hz
8452.119 Hz
8548.324 Hz
8749.383 Hz
8782.421 Hz
8784.424 Hz
8887.182 Hz
8894.222 Hz
8923.1 Hz
8923.361 Hz
8935.752 Hz
8936.1 Hz
9012.282 Hz
9012.896 Hz
9060.323 Hz
9072.409 Hz
9131.419 Hz
9199.232 Hz
9245.927 Hz
9270.322 Hz
9279.193 Hz
9393.946 Hz
10227.242 Hz
10340.509 Hz
10363.313 Hz
10449.323 Hz
10456.383 Hz
10468.231 Hz
10470.456 Hz
10472.291 Hz
10689.339 Hz
10832.222 Hz
11525.121 Hz
11541.915 Hz
11812.328 Hz
11812.419 Hz
11840.323 Hz
11925.089 Hz
12123.281 Hz
12267.281 Hz
12294.283 Hz
12334.419 Hz
12611.288 Hz
12629.222 Hz
12633.372 Hz
12648.221 Hz
13315.335 Hz
13331.358 Hz
13735.241 Hz
13826.325 Hz
13853.232 Hz
13915.231 Hz
13990.123 Hz
14122.942 Hz
14162.332 Hz
14519.232 Hz
14543.128 Hz
15651.323 Hz
17352.085 Hz
17970.122 Hz
18524.419 Hz
18619.331 Hz
18662.112 Hz
18679.492 Hz
18785.463 Hz
19385.893 Hz
19406.211 Hz
22479.333 Hz
30182.932 Hz
Example 2 AM Frequencies Employed for Treatment of Hepatocellular Carcinoma (Liver) Cancer (253 Frequencies so Far Included)
380.293 Hz
410.231 Hz
423.321 Hz
427.062 Hz
434.332 Hz
470.181 Hz
560.32 Hz
642.932 Hz
655.435 Hz
657.394 Hz
668.209 Hz
677.972 Hz
728.232 Hz
806.021 Hz
811.924 Hz
842.311 Hz
843.22 Hz
845.208 Hz
891.901 Hz
914.219 Hz
920.321 Hz
964.394 Hz
1250.504 Hz
1755.402 Hz
1814.223 Hz
1851.202 Hz
1873.477 Hz
1924.702 Hz
1975.196 Hz
2017.962 Hz
2053.396 Hz
2083.419 Hz
2190.731 Hz
2221.323 Hz
2308.294 Hz
2315.208 Hz
2324.393 Hz
2338.221 Hz
2353.478 Hz
2362.309 Hz
2379.571 Hz
2419.309 Hz
2425.222 Hz
2430.219 Hz
2431.094 Hz
2471.328 Hz
2478.331 Hz
2480.191 Hz
2522.328 Hz
2743.995 Hz
2744.211 Hz
2831.951 Hz
2843.283 Hz
2859.891 Hz
2873.542 Hz
2886.232 Hz
3009.332 Hz
3020.286 Hz
3042.012 Hz
3044.213 Hz
3051.218 Hz
3076.892 Hz
3078.983 Hz
3086.443 Hz
3104.854 Hz
3127.232 Hz
3160.942 Hz
3161.331 Hz
3167.22 Hz
3206.315 Hz
3255.219 Hz
3267.433 Hz
3269.321 Hz
3281.432 Hz
3457.291 Hz
3505.229 Hz
3516.296 Hz
3530.188 Hz
3531.296 Hz
3546.323 Hz
3572.106 Hz
3576.189 Hz
3669.513 Hz
3923.221 Hz
3927.331 Hz
4013.932 Hz
4071.121 Hz
4079.951 Hz
4123.953 Hz
4161.889 Hz
4222.821 Hz
4238.402 Hz
4256.321 Hz
4289.296 Hz
4312.947 Hz
4375.962 Hz
4426.387 Hz
4428.185 Hz
4435.219 Hz
4471.188 Hz
4483.889 Hz
4486.384 Hz
4556.322 Hz
4629.941 Hz
4715.222 Hz
4732.211 Hz
4767.185 Hz
4873.333 Hz
4876.218 Hz
5086.281 Hz
5124.084 Hz
5133.121 Hz
5247.142 Hz
5270.834 Hz
5340.497 Hz
5520.218 Hz
5570.234 Hz
5882.292 Hz
5926.512 Hz
6037.311 Hz
6180.334 Hz
6329.195 Hz
6350.333 Hz
6361.321 Hz
6364.928 Hz
6383.321 Hz
6461.175 Hz
6661.109 Hz
6711.392 Hz
6733.331 Hz
6758.232 Hz
6779.482 Hz
6856.222 Hz
6877.183 Hz
6915.886 Hz
6980.525 Hz
7019.235 Hz
7041.321 Hz
7043.209 Hz
7078.307 Hz
7130.323 Hz
7144.142 Hz
7210.223 Hz
7232.343 Hz
7291.21 Hz
7482.245 Hz
7510.92 Hz
7529.233 Hz
7549.212 Hz
7650.028 Hz
7680.518 Hz
7692.522 Hz
7829.231 Hz
7862.209 Hz
7932.482 Hz
7935.423 Hz
7947.392 Hz
7979.308 Hz
8025.322 Hz
8028.339 Hz
8055.942 Hz
8072.134 Hz
8141.174 Hz
8208.285 Hz
8328.312 Hz
8336.383 Hz
8394.793 Hz
8432.181 Hz
8452.119 Hz
8460.944 Hz
8475.221 Hz
8492.193 Hz
8542.311 Hz
8779.229 Hz
8818.104 Hz
8852.329 Hz
8853.444 Hz
8858.179 Hz
8915.221 Hz
8939.212 Hz
8953.231 Hz
8993.239 Hz
9278.889 Hz
9332.397 Hz
9381.221 Hz
9520.333 Hz
9719.314 Hz
9740.219 Hz
9768.331 Hz
9773.111 Hz
9797.294 Hz
9819.511 Hz
9845.319 Hz
10015.419 Hz
10043.293 Hz
10317.499 Hz
10438.495 Hz
10443.311 Hz
10456.383 Hz
10579.425 Hz
10863.209 Hz
10866.382 Hz
11067.418 Hz
11149.935 Hz
11163.895 Hz
11195.509 Hz
11421.219 Hz
11802.821 Hz
11953.424 Hz
12024.502 Hz
12223.329 Hz
12228.369 Hz
12247.233 Hz
12260.933 Hz
12265.295 Hz
12267.233 Hz
12267.296 Hz
12274.219 Hz
12623.191 Hz
12633.372 Hz
12685.231 Hz
12721.423 Hz
12785.342 Hz
13433.323 Hz
13457.388 Hz
14085.222 Hz
14212.122 Hz
14226.313 Hz
14333.209 Hz
14537.331 Hz
14542.432 Hz
14655.03 Hz
14736.223 Hz
14828.234 Hz
15149.213 Hz
15237.489 Hz
15560.908 Hz
15717.221 Hz
16110.932 Hz
16144.343 Hz
17153.322 Hz
17660.109 Hz
18121.184 Hz
18265.238 Hz
18283.323 Hz
18863.292 Hz
18930.995 Hz
19970.311 Hz
20330.294 Hz
20365.284 Hz
22321.331 Hz
24119.295 Hz
24181.221 Hz
Example 3 AM Frequencies Employed for Treatment of Ovarian Cancer (371 Frequencies so Far Included)
78.76 Hz
181.821 Hz
367.211 Hz
403.218 Hz
410.245 Hz
414.817 Hz
436.332 Hz
447.942 Hz
481.191 Hz
489.292 Hz
537.914 Hz
559.292 Hz
608.321 Hz
618.407 Hz
621.321 Hz
655.435 Hz
657.394 Hz
657.397 Hz
657.483 Hz
664.211 Hz
694.689 Hz
708.787 Hz
708.8 Hz
708.821 Hz
708.822 Hz
734.921 Hz
749.221 Hz
764.232 Hz
778.295 Hz
779.403 Hz
806.021 Hz
806.389 Hz
809.313 Hz
824.327 Hz
825.145 Hz
835.129 Hz
839.521 Hz
841.208 Hz
843.312 Hz
925.309 Hz
956.984 Hz
958.929 Hz
985.313 Hz
1024.208 Hz
1102.635 Hz
1121.329 Hz
1159.738 Hz
1221.321 Hz
1372.207 Hz
1396.498 Hz
1502.181 Hz
1518.208 Hz
1552.123 Hz
1579.212 Hz
1624.802 Hz
1656.431 Hz
1670.699 Hz
1679.432 Hz
1696.403 Hz
1759.318 Hz
1762.938 Hz
1771.402 Hz
1775.313 Hz
1821.729 Hz
1990.482 Hz
2016.323 Hz
2031.448 Hz
2034.231 Hz
2050.282 Hz
2053.396 Hz
2082.234 Hz
2089.092 Hz
2221.323 Hz
2228.832 Hz
2229.515 Hz
2253.704 Hz
2254.329 Hz
2278.312 Hz
2332.949 Hz
2348.233 Hz
2381.443 Hz
2413.193 Hz
2415.243 Hz
2425.222 Hz
2433.321 Hz
2439.253 Hz
2465.23 Hz
2477.919 Hz
2669.177 Hz
2715.232 Hz
2733.843 Hz
2771.211 Hz
2802.339 Hz
2812.321 Hz
2831.386 Hz
2835.332 Hz
2851.347 Hz
2856.253 Hz
2873.542 Hz
2877.192 Hz
2885.322 Hz
2887.385 Hz
2894.972 Hz
2973.771 Hz
3080.592 Hz
3157.483 Hz
3160.321 Hz
3161.465 Hz
3185.129 Hz
3223.232 Hz
3238.148 Hz
3240.111 Hz
3249.529 Hz
3254.122 Hz
3262.145 Hz
3264.241 Hz
3265.121 Hz
3282.235 Hz
3283.392 Hz
3296.431 Hz
3314.321 Hz
3361.671 Hz
3366.311 Hz
3459.408 Hz
3461.322 Hz
3523.215 Hz
3527.233 Hz
3542.213 Hz
3590.376 Hz
3629.232 Hz
3632.793 Hz
3636.289 Hz
3637.085 Hz
3669.513 Hz
3770.189 Hz
3858.916 Hz
3872.321 Hz
3919.232 Hz
3941.739 Hz
3957.185 Hz
3975.228 Hz
3975.383 Hz
4061.131 Hz
4072.322 Hz
4139.322 Hz
4169.451 Hz
4174.259 Hz
4241.321 Hz
4243.393 Hz
4261.228 Hz
4279.113 Hz
4309.335 Hz
4314.188 Hz
4318.222 Hz
4328.928 Hz
4340.833 Hz
4380.321 Hz
4394.134 Hz
4412.252 Hz
4424.236 Hz
4439.341 Hz
4442.161 Hz
4447.221 Hz
4458.339 Hz
4556.322 Hz
4566.009 Hz
4579.981 Hz
4682.643 Hz
4718.331 Hz
4749.302 Hz
4765.331 Hz
4779.194 Hz
4912.923 Hz
4917.202 Hz
5011.325 Hz
5149.331 Hz
5228.172 Hz
5237.132 Hz
5313.353 Hz
5745.218 Hz
5757.897 Hz
5762.386 Hz
5812.322 Hz
5869.321 Hz
5882.292 Hz
5921.249 Hz
5991.932 Hz
6069.458 Hz
6071.319 Hz
6083.214 Hz
6111.819 Hz
6161.782 Hz
6169.341 Hz
6275.232 Hz
6294.929 Hz
6350.333 Hz
6356.321 Hz
6406.891 Hz
6407.207 Hz
6450.787 Hz
6477.098 Hz
6477.929 Hz
6478.338 Hz
6504.983 Hz
6543.421 Hz
6552.24 Hz
6661.09 Hz
6663.955 Hz
6753.338 Hz
6789.211 Hz
6851.323 Hz
6855.286 Hz
6875.232 Hz
6882.949 Hz
7047.223 Hz
7206.403 Hz
7232.214 Hz
7257.489 Hz
7276.209 Hz
7279.335 Hz
7281.219 Hz
7285.223 Hz
7285.693 Hz
7289.192 Hz
7326.229 Hz
7399.223 Hz
7429.212 Hz
7460.932 Hz
7480.228 Hz
7488.742 Hz
7495.763 Hz
7539.432 Hz
7564.185 Hz
7650.028 Hz
7689.728 Hz
7780.294 Hz
8021.921 Hz
8038.961 Hz
8040.322 Hz
8044.233 Hz
8054.413 Hz
8095.313 Hz
8141.174 Hz
8143.491 Hz
8164.332 Hz
8261.121 Hz
8302.285 Hz
8309.752 Hz
8372.532 Hz
8408.121 Hz
8424.229 Hz
8428.313 Hz
8430.142 Hz
8435.451 Hz
8486.421 Hz
8492.797 Hz
8548.324 Hz
8554.361 Hz
8562.965 Hz
8578.193 Hz
8579.323 Hz
8579.333 Hz
8597.409 Hz
8642.181 Hz
8655.818 Hz
8758.341 Hz
8779.323 Hz
8792.231 Hz
8819.127 Hz
8831.132 Hz
8863.232 Hz
9028.031 Hz
9049.205 Hz
9173.264 Hz
9175.311 Hz
9184.338 Hz
9186.919 Hz
9393.946 Hz
9482.409 Hz
9658.296 Hz
9737.211 Hz
9746.232 Hz
9859.322 Hz
9922.231 Hz
10020.213 Hz
10032.684 Hz
10435.191 Hz
10446.028 Hz
10449.221 Hz
10457.329 Hz
10478.221 Hz
10498.339 Hz
10545.313 Hz
10639.345 Hz
10720.221 Hz
10743.118 Hz
10813.981 Hz
10832.421 Hz
10838.243 Hz
10862.429 Hz
10865.127 Hz
10917.229 Hz
10977.188 Hz
11120.209 Hz
11143.409 Hz
11177.289 Hz
11177.409 Hz
11321.491 Hz
11359.093 Hz
11540.212 Hz
11673.031 Hz
11731.295 Hz
11793.886 Hz
11895.229 Hz
12074.531 Hz
12216.212 Hz
12223.329 Hz
12243.132 Hz
12253.329 Hz
12260.933 Hz
12262.853 Hz
12292.222 Hz
12357.353 Hz
12527.032 Hz
12668.194 Hz
12743.197 Hz
12755.333 Hz
12947.311 Hz
13477.293 Hz
13582.122 Hz
13636.082 Hz
13717.221 Hz
13756.503 Hz
13825.295 Hz
13829.195 Hz
14188.611 Hz
14410.949 Hz
14436.201 Hz
14528.429 Hz
14537.218 Hz
14563.821 Hz
14835.809 Hz
14947.184 Hz
14948.323 Hz
15429.139 Hz
15443.309 Hz
15450.183 Hz
16026.221 Hz
16062.401 Hz
16081.291 Hz
16144.343 Hz
16331.323 Hz
17316.328 Hz
17930.967 Hz
17932.432 Hz
17951.395 Hz
17970.122 Hz
18242.181 Hz
18254.323 Hz
18265.238 Hz
18337.222 Hz
18344.212 Hz
18378.321 Hz
18921.415 Hz
18926.951 Hz
18931.327 Hz
19124.197 Hz
19133.123 Hz
19321.231 Hz
19686.593 Hz
114508.332 Hz
Example 4 AM Frequencies Employed for Treatment of Prostate Cancer (228 Frequencies so Far Included)
331.3 Hz
331.358 Hz
403.218 Hz
430.439 Hz
436.231 Hz
461.233 Hz
522.2 Hz
522.213 Hz
618.4 Hz
618.407 Hz
618.8 Hz
656.295 Hz
657.394 Hz
657.397 Hz
657.4 Hz
657.483 Hz
659.033 Hz
694.4 Hz
694.689 Hz
694.7 Hz
741.4 Hz
741.421 Hz
749.221 Hz
752.9 Hz
752.933 Hz
776.194 Hz
785.219 Hz
786.332 Hz
793.331 Hz
809.205 Hz
819.322 Hz
840.133 Hz
844.8 Hz
844.822 Hz
847.332 Hz
929.1 Hz
1083.309 Hz
1102.635 Hz
1102.71 Hz
1240.336 Hz
1372.934 Hz
1444.288 Hz
1486.322 Hz
1563.332 Hz
1591.322 Hz
1670.699 Hz
1697.321 Hz
1708.195 Hz
1741.939 Hz
1743.521 Hz
2031.448 Hz
2050.282 Hz
2076.519 Hz
2156.332 Hz
2229.515 Hz
2243.121 Hz
2381.443 Hz
2440.489 Hz
2475.912 Hz
2477.919 Hz
2551.332 Hz
2579.435 Hz
2628.324 Hz
2669.328 Hz
2824.832 Hz
2887.829 Hz
2891.331 Hz
3081.523 Hz
3133.309 Hz
3249.529 Hz
3250.125 Hz
3251.815 Hz
3264.827 Hz
3278.329 Hz
3281.432 Hz
3348.783 Hz
3519.118 Hz
3539.962 Hz
3551.318 Hz
3556.439 Hz
3572.321 Hz
3615.223 Hz
3670.129 Hz
3681.341 Hz
3686.021 Hz
3753.382 Hz
3774.923 Hz
3867.692 Hz
3909.333 Hz
3916.321 Hz
4031.233 Hz
4031.933 Hz
4038.203 Hz
4047.233 Hz
4066.222 Hz
4081.743 Hz
4084.319 Hz
4139.322 Hz
4153.192 Hz
4223.795 Hz
4231.221 Hz
4241.321 Hz
4320.513 Hz
4329.152 Hz
4380.321 Hz
4417.312 Hz
4489.452 Hz
4549.808 Hz
4558.306 Hz
4579.324 Hz
4638.293 Hz
4740.322 Hz
4854.318 Hz
4882.322 Hz
4978.822 Hz
5237.152 Hz
5264.222 Hz
5289.195 Hz
5426.323 Hz
5431.542 Hz
5455.593 Hz
6168.131 Hz
6345.332 Hz
6347.433 Hz
6363.284 Hz
6418.331 Hz
6496.231 Hz
6538.295 Hz
6577.421 Hz
6590.328 Hz
6651.276 Hz
6706.431 Hz
6743.322 Hz
6783.282 Hz
6850.197 Hz
6855.286 Hz
6864.896 Hz
6871.943 Hz
6878.356 Hz
6898.489 Hz
6973.393 Hz
7118.332 Hz
7120.932 Hz
7143.231 Hz
7146.509 Hz
7192.505 Hz
7251.309 Hz
7251.322 Hz
7278.124 Hz
7278.933 Hz
7279.335 Hz
7299.119 Hz
7527.229 Hz
7589.925 Hz
7699.193 Hz
7832.331 Hz
7842.184 Hz
7852.393 Hz
7872.333 Hz
8023.32 Hz
8096.939 Hz
8245.801 Hz
8315.291 Hz
8357.305 Hz
8408.121 Hz
8432.209 Hz
8535.238 Hz
8552.431 Hz
8585.224 Hz
8923.361 Hz
8935.752 Hz
9015.253 Hz
9018.233 Hz
9068.231 Hz
9137.232 Hz
9156.321 Hz
9351.931 Hz
9393.946 Hz
9694.179 Hz
9984.405 Hz
10226.223 Hz
10390.232 Hz
10442.221 Hz
10449.343 Hz
10459.084 Hz
10514.768 Hz
10651.311 Hz
10689.339 Hz
10772.419 Hz
10818.452 Hz
10843.543 Hz
11118.322 Hz
11165.239 Hz
11985.353 Hz
12209.329 Hz
12308.321 Hz
12489.233 Hz
12583.339 Hz
13820.329 Hz
14013.123 Hz
14129.213 Hz
14171.434 Hz
14681.329 Hz
14759.131 Hz
14986.794 Hz
15930.249 Hz
16026.623 Hz
16888.912 Hz
17091.189 Hz
17880.954 Hz
18021.222 Hz
18053.233 Hz
18247.532 Hz
18282.211 Hz
18610.232 Hz
18629.328 Hz
19469.318 Hz
19766.218 Hz
20159.434 Hz
21643.232 Hz
23022.481 Hz
23035.132 Hz
26718.23 Hz
30583.383 Hz
30653.323 Hz
30843.222 Hz
36065.221 Hz
60317.352 Hz
Example 5 AM Frequencies Employed for Treatment of Kidney Cancer (40 Frequencies so Far Included)
628.321 Hz
631.141 Hz
643.312 Hz
812.512 Hz
826.321 Hz
1240.336 Hz
1372.934 Hz
2082.241 Hz
2156.931 Hz
2254.329 Hz
2286.5 Hz
3555.209 Hz
3928.343 Hz
4329.152 Hz
4420.932 Hz
4819.228 Hz
4828.321 Hz
5314.322 Hz
6007.332 Hz
7054.279 Hz
7074.429 Hz
7254.343 Hz
8041.289 Hz
8727.224 Hz
8760.983 Hz
8831.132 Hz
8870.228 Hz
8923.1 Hz
10565.321 Hz
10586.229 Hz
10634.293 Hz
10687.949 Hz
11421.933 Hz
11523.212 Hz
11561.221 Hz
11846.212 Hz
12631.331 Hz
12693.272 Hz
14411.321 Hz
20178.941 Hz
Example 6 AM Frequencies Employed for Treatment of Thyroid Cancer (224 Frequencies so Far Included)
410.231 Hz
412.209 Hz
479.222 Hz
493.442 Hz
517.202 Hz
556.233 Hz
617.313 Hz
618.407 Hz
618.813 Hz
618.927 Hz
621.321 Hz
628.321 Hz
648.252 Hz
658.191 Hz
663.407 Hz
694.689 Hz
777.432 Hz
812.512 Hz
814.251 Hz
820.907 Hz
821.202 Hz
831.223 Hz
874.341 Hz
914.429 Hz
941.311 Hz
942.331 Hz
983.429 Hz
1127.239 Hz
1191.341 Hz
1380.828 Hz
1552.123 Hz
1587.811 Hz
1614.409 Hz
1723.389 Hz
1771.402 Hz
2155.311 Hz
2179.231 Hz
2185.282 Hz
2221.323 Hz
2228.832 Hz
2315.888 Hz
2341.312 Hz
2445.123 Hz
2454.232 Hz
2723.302 Hz
2740.384 Hz
2749.323 Hz
2856.253 Hz
2856.921 Hz
2859.495 Hz
2871.795 Hz
2886.232 Hz
2928.911 Hz
2988.212 Hz
3021.122 Hz
3078.275 Hz
3080.592 Hz
3186.331 Hz
3198.323 Hz
3248.321 Hz
3271.329 Hz
3284.192 Hz
3335.332 Hz
3432.343 Hz
3434.911 Hz
3440.212 Hz
3475.216 Hz
3509.522 Hz
3533.328 Hz
3610.203 Hz
3637.085 Hz
3682.489 Hz
3789.288 Hz
3822.392 Hz
3909.333 Hz
3917.211 Hz
4023.33 Hz
4028.204 Hz
4043.332 Hz
4046.321 Hz
4154.301 Hz
4207.322 Hz
4226.263 Hz
4236.945 Hz
4243.393 Hz
4261.228 Hz
4330.289 Hz
4340.833 Hz
4347.125 Hz
4358.333 Hz
4366.294 Hz
4426.387 Hz
4440.962 Hz
4458.339 Hz
4478.443 Hz
4479.113 Hz
4486.193 Hz
4744.424 Hz
4827.642 Hz
4854.318 Hz
4865.421 Hz
4897.212 Hz
5323.192 Hz
5324.123 Hz
5548.879 Hz
5711.283 Hz
5730.432 Hz
5754.332 Hz
5881.295 Hz
5924.221 Hz
6455.131 Hz
6558.342 Hz
6620.132 Hz
6666.839 Hz
6675.951 Hz
6714.189 Hz
6745.333 Hz
6766.281 Hz
6779.088 Hz
6780.679 Hz
6884.432 Hz
6917.194 Hz
6946.928 Hz
7036.122 Hz
7083.191 Hz
7230.838 Hz
7323.209 Hz
7355.378 Hz
7432.143 Hz
7495.763 Hz
7505.282 Hz
7534.221 Hz
7577.421 Hz
7623.184 Hz
7626.332 Hz
7725.339 Hz
7726.085 Hz
7920.879 Hz
8013.953 Hz
8019.912 Hz
8021.331 Hz
8040.231 Hz
8078.955 Hz
8082.173 Hz
8147.1 Hz
8281.259 Hz
8309.752 Hz
8311.371 Hz
8435.094 Hz
8442.293 Hz
8505.312 Hz
8521.311 Hz
8525.789 Hz
8537.321 Hz
8540.329 Hz
8543.211 Hz
8553.329 Hz
8744.527 Hz
8881.819 Hz
9009.329 Hz
9068.311 Hz
9070.809 Hz
9085.911 Hz
9535.393 Hz
9720.412 Hz
10020.521 Hz
10039.109 Hz
10127.279 Hz
10134.161 Hz
10257.324 Hz
10498.339 Hz
10765.224 Hz
10849.412 Hz
10924.342 Hz
10976.321 Hz
11030.418 Hz
11360.332 Hz
11537.292 Hz
11559.292 Hz
11812.119 Hz
11913.222 Hz
11927.934 Hz
11955.949 Hz
11960.179 Hz
12120.049 Hz
12139.222 Hz
12146.335 Hz
12489.233 Hz
12984.462 Hz
13425.229 Hz
13636.082 Hz
13654.272 Hz
13677.211 Hz
14014.941 Hz
14228.295 Hz
14445.214 Hz
14540.932 Hz
14823.325 Hz
14826.334 Hz
14910.894 Hz
15180.492 Hz
15561.322 Hz
15597.284 Hz
16023.119 Hz
16048.391 Hz
16080.831 Hz
16129.321 Hz
16539.532 Hz
17222.225 Hz
17253.222 Hz
17323.196 Hz
17461.504 Hz
17577.221 Hz
17671.321 Hz
17881.709 Hz
17911.323 Hz
17913.286 Hz
17937.203 Hz
17948.264 Hz
18036.921 Hz
18715.412 Hz
19859.429 Hz
21425.321 Hz
21452.445 Hz
Example 7 AM Frequencies Employed for Treatment of Bladder Cancer (31 Frequencies so Far Included)
623.243 Hz
757.084 Hz
870.4 Hz
2454.423 Hz
2480.191 Hz
2581.101 Hz
2715.232 Hz
3042.012 Hz
3196.194 Hz
3265.323 Hz
3438.109 Hz
3692.319 Hz
3952.308 Hz
5230.227 Hz
6022.942 Hz
6061.711 Hz
6710.899 Hz
6721.912 Hz
7181.784 Hz
7212.826 Hz
7458.209 Hz
8235.21 Hz
8749.232 Hz
8767.189 Hz
9354.812 Hz
9611.339 Hz
12532.729 Hz
13467.209 Hz
13777.9 Hz
14015.241 Hz
18524.419 Hz
Example 8 AM Frequencies Employed for Treatment of Colon Cancer (100 Frequencies so Far Included)
78.76 Hz
796.562 Hz
841.541 Hz
842.783 Hz
914.429 Hz
1162.117 Hz
1372.207 Hz
1372.934 Hz
1718.532 Hz
2243.169 Hz
2278.312 Hz
2286.5 Hz
2286.519 Hz
2334.178 Hz
2423.292 Hz
2454.423 Hz
2464.229 Hz
2598.853 Hz
2623.048 Hz
3131.123 Hz
3161.465 Hz
3175.313 Hz
3249.529 Hz
3363.229 Hz
3373.892 Hz
3390.925 Hz
3409.179 Hz
3432.274 Hz
3509.522 Hz
3531.422 Hz
3533.328 Hz
3766.296 Hz
4040.839 Hz
4081.022 Hz
4123.953 Hz
4146.274 Hz
4233.822 Hz
4282.332 Hz
4318.222 Hz
4344.082 Hz
4416.221 Hz
4481.242 Hz
4724.263 Hz
4751.319 Hz
4755.323 Hz
4788.485 Hz
5149.331 Hz
5217.402 Hz
5386.212 Hz
5407.192 Hz
5426.323 Hz
5496.434 Hz
5555.212 Hz
5572.032 Hz
5634.933 Hz
5724.231 Hz
5758.378 Hz
5787.342 Hz
5948.897 Hz
5967.448 Hz
5976.825 Hz
6182.322 Hz
6292.379 Hz
6324.493 Hz
6341.248 Hz
6471.322 Hz
6477.218 Hz
6558.342 Hz
6855.286 Hz
7129.843 Hz
7140.187 Hz
7162.422 Hz
7368.222 Hz
7645.859 Hz
7829.234 Hz
7866.229 Hz
7877.334 Hz
8013.314 Hz
8374.942 Hz
8384.228 Hz
8408.121 Hz
8534.111 Hz
8568.033 Hz
8573.122 Hz
9226.222 Hz
9351.9 Hz
9737.211 Hz
9744.193 Hz
9942.321 Hz
10301.371 Hz
10401.515 Hz
10872.693 Hz
11220.222 Hz
11283.378 Hz
12256.432 Hz
13749.858 Hz
15231.548 Hz
15248.324 Hz
58191.928 Hz
60317.352 Hz
Example 9 AM Frequencies Employed for Treatment of Pancreas Cancer (166 Frequencies so Far Included)
331.3 Hz
331.365 Hz
436.3 Hz
436.332 Hz
447.942 Hz
476.127 Hz
559.292 Hz
589.187 Hz
624.218 Hz
727 Hz
734.921 Hz
809.313 Hz
845.309 Hz
870.4 Hz
963.221 Hz
1156.79 Hz
1157 Hz
1179 Hz
1360.133 Hz
1372.207 Hz
1372.934 Hz
1804.126 Hz
1816.221 Hz
1873.477 Hz
1967.211 Hz
1990.482 Hz
2278.312 Hz
2315.921 Hz
2320.315 Hz
2334.178 Hz
2381.443 Hz
2469 Hz
2477.919 Hz
2542.221 Hz
2598.853 Hz
2647.938 Hz
2685.081 Hz
2716.095 Hz
2721.331 Hz
2732.231 Hz
2809.849 Hz
2823.428 Hz
2835.332 Hz
3134.313 Hz
3241.461 Hz
3255.219 Hz
3263.432 Hz
3286.255 Hz
3330.935 Hz
3373.892 Hz
3438.109 Hz
3449.219 Hz
3535.219 Hz
3549.215 Hz
3564.419 Hz
3619.412 Hz
3622.312 Hz
3638.432 Hz
3696.424 Hz
3943.214 Hz
3976.929 Hz
4014.889 Hz
4041.219 Hz
4044.195 Hz
4056.384 Hz
4085.971 Hz
4144.592 Hz
4153.192 Hz
4161.889 Hz
4243.393 Hz
4332.498 Hz
4341.423 Hz
4355.327 Hz
4417.885 Hz
4422.322 Hz
4451.297 Hz
4486.384 Hz
4558.306 Hz
4580 Hz
4685.082 Hz
4839.589 Hz
5151.402 Hz
5209.911 Hz
5262.282 Hz
5271.312 Hz
5387.73 Hz
5494.928 Hz
5521.221 Hz
5573.209 Hz
5609.382 Hz
5929.616 Hz
5948.897 Hz
5966.112 Hz
5976.825 Hz
6064.197 Hz
6086.256 Hz
6157.253 Hz
6215.298 Hz
6333.917 Hz
6365.242 Hz
6558.342 Hz
6568.278 Hz
6823.194 Hz
6853.391 Hz
6855.286 Hz
7213.204 Hz
7228.528 Hz
7238.232 Hz
7277.921 Hz
7280.422 Hz
7320.494 Hz
7366.412 Hz
7534.221 Hz
7548.713 Hz
7567.127 Hz
7620.851 Hz
7663.209 Hz
7725.203 Hz
7852.233 Hz
7920.879 Hz
7985.122 Hz
8008.323 Hz
8013.312 Hz
8045.484 Hz
8242.332 Hz
8351.622 Hz
8408.121 Hz
8455.894 Hz
8551.231 Hz
8743.321 Hz
8789.631 Hz
8868.809 Hz
9012.241 Hz
9028.994 Hz
9131.232 Hz
9658.296 Hz
9663.495 Hz
9680.737 Hz
9824.442 Hz
9942.321 Hz
10279.122 Hz
10388.49 Hz
10438.495 Hz
10518.311 Hz
10528.239 Hz
10582.095 Hz
10926.111 Hz
10948.411 Hz
10955.558 Hz
11538.193 Hz
11904.741 Hz
12255.229 Hz
12613.341 Hz
12819.942 Hz
13674.482 Hz
13731.322 Hz
14525.312 Hz
14537.218 Hz
14549.331 Hz
14845.453 Hz
14944.989 Hz
15246.315 Hz
18668.239 Hz
19321.231 Hz
19347.208 Hz
30182.932 Hz
Example 10 AM Frequencies Employed for Treatment of Lung Cancer (80 Frequencies so Far Included)
304.148 Hz
694.7 Hz
694.727 Hz
708.8 Hz
708.841 Hz
1587.811 Hz
1759.318 Hz
1873.477 Hz
2253.704 Hz
2391.312 Hz
2454.232 Hz
2729.929 Hz
2741.261 Hz
2761.312 Hz
2784.491 Hz
2812.443 Hz
2855.218 Hz
2859.495 Hz
3128.822 Hz
3139.297 Hz
3193.212 Hz
3348.783 Hz
3360.971 Hz
3366.311 Hz
3373.892 Hz
3440.212 Hz
3461.322 Hz
3682.489 Hz
3727.231 Hz
3749.882 Hz
3769.942 Hz
4131.235 Hz
4158.393 Hz
4243.393 Hz
4347.733 Hz
4373.411 Hz
4378.321 Hz
4416.221 Hz
4481.242 Hz
4777.521 Hz
4798.422 Hz
4837.241 Hz
4959.842 Hz
5013.321 Hz
5047.523 Hz
5068.322 Hz
5371.922 Hz
5538.432 Hz
5548.879 Hz
5679.309 Hz
5734.143 Hz
5787.342 Hz
6445.309 Hz
6838.434 Hz
6870.955 Hz
6879.216 Hz
7079.411 Hz
7216.288 Hz
7376.089 Hz
7761.289 Hz
8082.173 Hz
8281.259 Hz
8352.189 Hz
8442.473 Hz
8773.916 Hz
8935.752 Hz
9121.223 Hz
9181.434 Hz
9317.913 Hz
9363.896 Hz
9736.919 Hz
9753.321 Hz
10424.908 Hz
10452.913 Hz
10824.609 Hz
11656.329 Hz
12748.919 Hz
15774.291 Hz
15798.333 Hz
16510.333 Hz
Example 11 AM Frequencies Employed for Treatment of Leiomyosarcoma (36 Frequencies so Far Included)
836.923 Hz
843.181 Hz
1411.241 Hz
2073.721 Hz
2381.443 Hz
2711.019 Hz
2911.329 Hz
3232.185 Hz
3518.321 Hz
3544.209 Hz
3569.219 Hz
4233.822 Hz
4241.321 Hz
4266.591 Hz
4337.322 Hz
4424.112 Hz
4436.111 Hz
4485.22 Hz
5545.521 Hz
5577.841 Hz
5631.422 Hz
5696.184 Hz
6472.098 Hz
6558.342 Hz
6651.276 Hz
7168.892 Hz
7406.309 Hz
7452.528 Hz
7649.209 Hz
7808.352 Hz
9040.313 Hz
9074.294 Hz
9189.092 Hz
9484.512 Hz
9943.972 Hz
12086.394 Hz
Example 12 AM Frequencies Employed for Treatment of Mesothelioma (16 Frequencies so Far Included)
 958.929 Hz
1713.913 Hz
1736.782 Hz
2334.178 Hz
2607.193 Hz
3112.974 Hz
3319.945 Hz
3449.219 Hz
3622.312 Hz
5151.402 Hz
5887.022 Hz
5965.922 Hz
6516.793 Hz
7224.197 Hz
9471.152 Hz
14617.393 Hz 
Example 13 AM Frequencies Employed for Treatment of Neuro-Endocrine (30 Frequencies so Far Included)
1766.335 Hz
2408.225 Hz
2441.502 Hz
2647.938 Hz
2741.261 Hz
3020.212 Hz
3128.822 Hz
3238.742 Hz
3296.431 Hz
3348.783 Hz
3360.971 Hz
3440.212 Hz
3533.328 Hz
3666.283 Hz
4079.282 Hz
4243.393 Hz
4426.387 Hz
5245.818 Hz
5536.242 Hz
5548.879 Hz
5739.422 Hz
5849.241 Hz
6291.631 Hz
6406.891 Hz
6780.679 Hz
7151.264 Hz
7482.245 Hz
7575.393 Hz
8359.932 Hz
9073.418 Hz
Example 14 AM Frequencies Employed for Treatment of Leukemia and Chronic Lymphoid Cancer (17 Frequencies so Far Included)
 814.413 Hz
 825.145 Hz
2415.243 Hz
2436.316 Hz
2874.432 Hz
2891.029 Hz
3361.671 Hz
5245.452 Hz
5557.333 Hz
6850.197 Hz
6919.322 Hz
7587.224 Hz
7629.318 Hz
8172.405 Hz
8272.338 Hz
8438.453 Hz
12950.331 Hz 
Example 15 AM Frequencies Employed for Treatment of Myeloma, Multiple Cancer (20 Frequencies so Far Included)
 765.196 Hz
2336.238 Hz
2372.122 Hz
2381.443 Hz
2425.394 Hz
2656.339 Hz
2741.261 Hz
2883.618 Hz
2919.273 Hz
3265.323 Hz
3564.455 Hz
 3580.25 Hz
3584.291 Hz
3674.292 Hz
5249.331 Hz
7967.311 Hz
7973.125 Hz
8049.952 Hz
8283.329 Hz
10351.323 Hz 
Example 16 AM Frequencies Employed for Treatment of Hodgkin Disease (Lymphoma) (19 Frequencies so Far Included)
752.5 Hz
976.3 Hz
1558.223 Hz
2310.912 Hz
2477.919 Hz
2560.843 Hz
3348.783 Hz
3371.216 Hz
3605.432 Hz
3623.198 Hz
3838.281 Hz
3838.48 Hz
5102 Hz
5696.932 Hz
5724.231 Hz
6358.194 Hz
7472.211 Hz
8062.121 Hz
8222.222 Hz
Example 17 AM Frequencies Employed for Treatment of Brain Cancer (57 Frequencies so Far Included)
1372.934 Hz
2318.182 Hz
2381.443 Hz
2425.394 Hz
2442.423 Hz
2478.973 Hz
2654.513 Hz
2661.324 Hz
2686.105 Hz
2690.179 Hz
3249.332 Hz
3277.509 Hz
3335.279 Hz
3348.783 Hz
3436.211 Hz
3916.321 Hz
4031.933 Hz
4086.091 Hz
4241.321 Hz
4318.222 Hz
4334.33 Hz
4358.333 Hz
4393.419 Hz
4454.194 Hz
4515.789 Hz
4619.324 Hz
4723.937 Hz
4853.286 Hz
5289.231 Hz
5378.099 Hz
5426.323 Hz
5640.981 Hz
6316.211 Hz
6459.203 Hz
6474.332 Hz
6626.572 Hz
6855.286 Hz
6915.886 Hz
6943.386 Hz
7151.264 Hz
7182.922 Hz
7194.897 Hz
7323.209 Hz
7390.343 Hz
7796.221 Hz
7961.122 Hz
8128.942 Hz
8245.109 Hz
8272.281 Hz
8358.154 Hz
8408.121 Hz
9138.82 Hz
10719.318 Hz
11556.241 Hz
12828.633 Hz
14515.962 Hz
14586.765 Hz
The above Examples reflect AM frequencies determined by a bio-feedback procedure involving very substantial observations and measurements of physiological responses (at certain well defined AM frequencies) by subjects exposed to low energy electromagnetic emission excitation. In general, it is recommended that all of the listed frequencies be applied in the treatment of subjects suffering from the indicated form of cancer. However, a limited number of the listed frequencies also lead to beneficial effects.
Of note in respect of the above listed frequencies, in particular those Examples including a large number of frequencies, it has earlier on been determined that beneficial therapeutic effects are achieved by application of some but not all of the frequencies listed. However, following on more extended trials, it has been determined that application to subjects of further frequencies enhance the efficacy of treatment and yields therapeutic effects in patients whose tumors have become resistant to therapy. It is accordingly preferred that all of the determined listed frequencies be applied to the subject. The mechanism of including additional frequencies is attributed to either or both of inter-active synergism between applied frequencies or between cells which have been influenced by the treatment and additive effects of the additional frequencies.
Of further note is the fact that different patients suffering from the same type of tumor cell growth practically invariably exhibit the above-mentioned physiological responses at the same well defined AM frequencies. Furthermore, AM frequencies which differ only very slightly (less than 0.0001% at higher frequencies) from the frequencies listed, in general elicit no physiological response by subjects exposed to excitation at such very slightly different frequency. In view of these determinations, the electronic system of the present invention may be adapted to screen a subject for physiological responses over a broad range of frequencies to determine the presence or absence tumor cells and, if positive, then to note at which defined frequencies physiological responses are elicited. These frequencies will in general match with the defined frequencies listed in one or other of the Examples above or such further examples as may be developed and hence the nature of the tumor will be known. The electronic system of the invention is therefore a valuable diagnostic tool for diagnosing the presence or absence and identities of types of tumor cell growths or cancers. Furthermore, the electronic system of the invention is of value for predicting whether a patient will benefit from the application of a given series of modulation frequencies. The system therefore possesses a capability of predicting responses to treatment, thereby enhancing the possibility to select optimal modes. of treatment.
The sequence of well defined frequencies are preferably applied sequentially for determined periods of time, e.g., 3 seconds for each frequency, but several frequencies may also be applied simultaneously. This means that a cycle of application involving 180 frequencies would take nearly 10 minutes time. Advantageous effects may however also arise from applying individual well defined frequencies for differing time periods, e.g., some for 3 seconds, some for 6 seconds, etc.
Therapeutic dosages to be applied to a subject suffering from the presence of tumor cell growth or cancer are determined by the time of application of the low energy electromagnetic emissions to the subject and will depend on the nature of the cancer and the overall condition of the subject. In general, however, greatest experience has been gained in treating terminally ill subjects expected to survive no longer than about three months and who have agreed to discontinue alternative forms of cancer treatments such as chemo-therapy or radioactive treatment. In these severe cases, lengthy times of treatment are recommended, e.g., 3 times 1 hour daily treatment. However, with the development of alternative forms of application, i.e., other than by means of a mouth probe, continuous application is possible and is likely to enhance compliance and the efficacy of the treatment.
While the invention has been described with specific embodiments, other alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it will be intended to include all such alternatives, modifications, and variations within the spirit and scope of the appended claims.

Claims (18)

It is claimed:
1. An electronic system activatable by electrical power and structured to inhibit proliferation of cancerous cells or to kill cancerous cells harboured by a warm-blooded mammalian subject, said electronic system comprising at least one controllable low energy electromagnetic energy generator circuit for generating one or more high frequency carrier signals, at least one data processor constructed and arranged for communication with the at least one generator circuit and for receiving control information from a source of control information, said at least one generator circuit including at least one amplitude modulation control signal generator for controlling amplitude modulated variations of the one or more high frequency carrier signals, said at least one generator circuit furthermore including at least one programmable amplitude modulation frequency control signal generator for controlling frequencies at which amplitude modulations are generated, the system furthermore comprising a connection position for connection to an electrically conductive applicator for applying to the warm-blooded mammalian subject one or more amplitude-modulated low energy emissions at a program-controlled frequency, wherein said at least one programmable amplitude frequency control generator is adapted to accurately control the frequencies at which said amplitude modulations are generated to within an accuracy of at least 1000 parts per million relative to determined or predetermined reference amplitude modulation frequencies selected from within a range of 0.01 Hz to 150 kHz and wherein said source of control information includes reference amplitude modulation frequency control information which comprises a selection of from at least a proportion in excess of 50% to all of reference amplitude modulation frequencies accurately defined for a type of the cancerous cells to be inhibited in proliferation or killed, wherein said selection of the reference amplitude modulation frequencies accurately defined comprised in said source control information is made dependent on the type of cancerous cells to be inhibited in proliferation or killed identified as set forth in combination with listings of the reference amplitude modulation frequencies accurately defined as follows:
(1) frequencies for treatment of breast cancer as follows
78.76 Hz 181.821 Hz 331.3 Hz 414.817 Hz 430.439 Hz 440.933 Hz 618.8 Hz 628.431 Hz 655.435 Hz 677.972 Hz 721.313 Hz 752.933 Hz 813.205 Hz 818.342 Hz 825.145 Hz 839.521 Hz 841.211 Hz 843.312 Hz 891.901 Hz 929.095 Hz 929.1 Hz 929.131 Hz 958.929 Hz 1021 Hz 1021.311 Hz 1156.79 Hz 1372.207 Hz 1372.934 Hz 1555.282 Hz 1588.721 Hz 1624.802 Hz 1670.699 Hz 1821.729 Hz 1836.219 Hz 2193.937 Hz 2221.323 Hz 2278.312 Hz 2332.949 Hz 2357.832 Hz 2381.443 Hz 2417.323 Hz 2423.292 Hz 2431.334 Hz 2450.332 Hz 2551.313 Hz 2556.221 Hz 2598.853 Hz 2621.322 Hz 2740.191 Hz 2823.428 Hz 2831.386 Hz 2851.347 Hz 2885.322 Hz 2919.273 Hz 3074.333 Hz 3115.188 Hz 3239.212 Hz 3249.529 Hz 3405.182 Hz 3432.274 Hz 3434.693 Hz 3594.231 Hz 3647.619 Hz 3657.931 Hz 3742.957 Hz 3753.382 Hz 3830.732 Hz 3855.823 Hz 3916.321 Hz 3935.218 Hz 3975.383 Hz 3993.437 Hz 4153.192 Hz 4194.968 Hz 4241.321 Hz 4243.393 Hz 4253.432 Hz 4314.444 Hz 4318.222 Hz 4375.962 Hz 4393.419 Hz 4394.134 Hz 4417.243 Hz 4481.463 Hz 4482.223 Hz 4495.138 Hz 4549.808 Hz 4558.306 Hz 4751.908 Hz 4779.451 Hz 4838.674 Hz 4871.513 Hz 4878.687 Hz 4895.296 Hz 4962.213 Hz 4969.224 Hz 4979.321 Hz 5027.231 Hz 5059.792 Hz 5118.094 Hz 5176.287 Hz 5365.222 Hz 5376.392 Hz 5426.323 Hz 5431.542 Hz 5521.621 Hz 5536.242 Hz 5739.422 Hz 5745.218 Hz 5821.975 Hz 6037.432 Hz 6044.333 Hz 6086.256 Hz 6208.932 Hz 6212.808 Hz 6231.031 Hz 6280.321 Hz 6329.391 Hz 6476.896 Hz 6477.098 Hz 6497.319 Hz 6504.983 Hz 6651.276 Hz 6657.913 Hz 6757.901 Hz 6758.321 Hz 6855.286 Hz 6858.121 Hz 6898.489 Hz 6915.886 Hz 7092.219 Hz 7120.218 Hz 7127.311 Hz 7156.489 Hz 7208.821 Hz 7224.197 Hz 7282.169 Hz 7285.693 Hz 7376.329 Hz 7488.742 Hz 7541.319 Hz 7577.421 Hz 7621.085 Hz 7627.207 Hz 7650.939 Hz 7668.231 Hz 7691.212 Hz 7842.184 Hz 7849.231 Hz 7915.423 Hz 7932.482 Hz 7949.196 Hz 7967.311 Hz 8021.229 Hz 8070.181 Hz 8114.032 Hz 8149.922 Hz 8194.19 Hz 8245.801 Hz 8328.322 Hz 8330.534 Hz 8355.987 Hz 8408.121 Hz 8431.184 Hz 8452.119 Hz 8548.324 Hz 8749.383 Hz 8782.421 Hz 8784.424 Hz 8887.182 Hz 8894.222 Hz 8923.1 Hz 8923.361 Hz 8935.752 Hz 8936.1 Hz 9012.282 Hz 9012.896 Hz 9060.323 Hz 9072.409 Hz 9131.419 Hz 9199.232 Hz 9245.927 Hz 9270.322 Hz 9279.193 Hz 9393.946 Hz 10227.242 Hz 10340.509 Hz 10363.313 Hz 10449.323 Hz 10456.383 Hz 10468.231 Hz 10470.456 Hz 10472.291 Hz 10689.339 Hz 10832.222 Hz 11525.121 Hz 11541.915 Hz 11812.328 Hz 11812.419 Hz 11840.323 Hz 11925.089 Hz 12123.281 Hz 12267.281 Hz 12294.283 Hz 12334.419 Hz 12611.288 Hz 12629.222 Hz 12633.372 Hz 12648.221 Hz 13315.335 Hz 13331.358 Hz 13735.241 Hz 13826.325 Hz 13853.232 Hz 13915.231 Hz 13990.123 Hz 14122.942 Hz 14162.332 Hz 14519.232 Hz 14543.128 Hz 15651.323 Hz 17352.085 Hz 17970.122 Hz 18524.419 Hz 18619.331 Hz 18662.112 Hz 18679.492 Hz 18785.463 Hz 19385.893 Hz 19406.211 Hz 22479.333 Hz 30182.932 Hz;
(2) frequencies for treatment of hepatocellular carcinoma (liver cancer) as follows
380.293 Hz 410.231 Hz 423.321 Hz 427.062 Hz 434.332 Hz 470.181 Hz 560.32 Hz 642.932 Hz 655.435 Hz 657.394 Hz 668.209 Hz 677.972 Hz 728.232 Hz 806.021 Hz 811.924 Hz 842.311 Hz 843.22 Hz 845.208 Hz 891.901 Hz 914.219 Hz 920.321 Hz 964.394 Hz 1250.504 Hz 1755.402 Hz 1814.223 Hz 1851.202 Hz 1873.477 Hz 1924.702 Hz 1975.196 Hz 2017.962 Hz 2053.396 Hz 2083.419 Hz 2190.731 Hz 2221.323 Hz 2308.294 Hz 2315.208 Hz 2324.393 Hz 2338.221 Hz 2353.478 Hz 2362.309 Hz 2379.571 Hz 2419.309 Hz 2425.222 Hz 2430.219 Hz 2431.094 Hz 2471.328 Hz 2478.331 Hz 2480.191 Hz 2522.328 Hz 2743.995 Hz 2744.211 Hz 2831.951 Hz 2843.283 Hz 2859.891 Hz 2873.542 Hz 2886.232 Hz 3009.332 Hz 3020.286 Hz 3042.012 Hz 3044.213 Hz 3051.218 Hz 3076.892 Hz 3078.983 Hz 3086.443 Hz 3104.854 Hz 3127.232 Hz 3160.942 Hz 3161.331 Hz 3167.22 Hz 3206.315 Hz 3255.219 Hz 3267.433 Hz 3269.321 Hz 3281.432 Hz 3457.291 Hz 3505.229 Hz 3516.296 Hz 3530.188 Hz 3531.296 Hz 3546.323 Hz 3572.106 Hz 3576.189 Hz 3669.513 Hz 3923.221 Hz 3927.331 Hz 4013.932 Hz 4071.121 Hz 4079.951 Hz 4123.953 Hz 4161.889 Hz 4222.821 Hz 4238.402 Hz 4256.321 Hz 4289.296 Hz 4312.947 Hz 4375.962 Hz 4426.387 Hz 4428.185 Hz 4435.219 Hz 4471.188 Hz 4483.889 Hz 4486.384 Hz 4556.322 Hz 4629.941 Hz 4715.222 Hz 4732.211 Hz 4767.185 Hz 4873.333 Hz 4876.218 Hz 5086.281 Hz 5124.084 Hz 5133.121 Hz 5247.142 Hz 5270.834 Hz 5340.497 Hz 5520.218 Hz 5570.234 Hz 5882.292 Hz 5926.512 Hz 6037.311 Hz 6180.334 Hz 6329.195 Hz 6350.333 Hz 6361.321 Hz 6364.928 Hz 6383.321 Hz 6461.175 Hz 6661.109 Hz 6711.392 Hz 6733.331 Hz 6758.232 Hz 6779.482 Hz 6856.222 Hz 6877.183 Hz 6915.886 Hz 6980.525 Hz 7019.235 Hz 7041.321 Hz 7043.209 Hz 7078.307 Hz 7130.323 Hz 7144.142 Hz 7210.223 Hz 7232.343 Hz 7291.21 Hz 7482.245 Hz 7510.92 Hz 7529.233 Hz 7549.212 Hz 7650.028 Hz 7680.518 Hz 7692.522 Hz 7829.231 Hz 7862.209 Hz 7932.482 Hz 7935.423 Hz 7947.392 Hz 7979.308 Hz 8025.322 Hz 8028.339 Hz 8055.942 Hz 8072.134 Hz 8141.174 Hz 8208.285 Hz 8328.312 Hz 8336.383 Hz 8394.793 Hz 8432.181 Hz 8452.119 Hz 8460.944 Hz 8475.221 Hz 8492.193 Hz 8542.311 Hz 8779.229 Hz 8818.104 Hz 8852.329 Hz 8853.444 Hz 8858.179 Hz 8915.221 Hz 8939.212 Hz 8953.231 Hz 8993.239 Hz 9278.889 Hz 9332.397 Hz 9381.221 Hz 9520.333 Hz 9719.314 Hz 9740.219 Hz 9768.331 Hz 9773.111 Hz 9797.294 Hz 9819.511 Hz 9845.319 Hz 10015.419 Hz 10043.293 Hz 10317.499 Hz 10438.495 Hz 10443.311 Hz 10456.383 Hz 10579.425 Hz 10863.209 Hz 10866.382 Hz 11067.418 Hz 11149.935 Hz 11163.895 Hz 11195.509 Hz 11421.219 Hz 11802.821 Hz 11953.424 Hz 12024.502 Hz 12223.329 Hz 12228.369 Hz 12247.233 Hz 12260.933 Hz 12265.295 Hz 12267.233 Hz 12267.296 Hz 12274.219 Hz 12623.191 Hz 12633.372 Hz 12685.231 Hz 12721.423 Hz 12785.342 Hz 13433.323 Hz 13457.388 Hz 14085.222 Hz 14212.122 Hz 14226.313 Hz 14333.209 Hz 14537.331 Hz 14542.432 Hz 14655.03 Hz 14736.223 Hz 14828.234 Hz 15149.213 Hz 15237.489 Hz 15560.908 Hz 15717.221 Hz 16110.932 Hz 16144.343 Hz 17153.322 Hz 17660.109 Hz 18121.184 Hz 18265.238 Hz 18283.323 Hz 18863.292 Hz 18930.995 Hz 19970.311 Hz 20330.294 Hz 20365.284 Hz 22321.331 Hz 24119.295 Hz 24181.221 Hz;
(3) frequencies for treatment of ovarian cancer as follows
78.76 Hz 181.821 Hz 367.211 Hz 403.218 Hz 410.245 Hz 414.817 Hz 436.332 Hz 447.942 Hz 481.191 Hz 489.292 Hz 537.914 Hz 559.292 Hz 608.321 Hz 618.407 Hz 621.321 Hz 655.435 Hz 657.394 Hz 657.397 Hz 657.483 Hz 664.211 Hz 694.689 Hz 708.787 Hz 708.8 Hz 708.821 Hz 708.822 Hz 734.921 Hz 749.221 Hz 764.232 Hz 778.295 Hz 779.403 Hz 806.021 Hz 806.389 Hz 809.313 Hz 824.327 Hz 825.145 Hz 835.129 Hz 839.521 Hz 841.208 Hz 843.312 Hz 925.309 Hz 956.984 Hz 958.929 Hz 985.313 Hz 1024.208 Hz 1102.635 Hz 1121.329 Hz 1159.738 Hz 1221.321 Hz 1372.207 Hz 1396.498 Hz 1502.181 Hz 1518.208 Hz 1552.123 Hz 1579.212 Hz 1624.802 Hz 1656.431 Hz 1670.699 Hz 1679.432 Hz 1696.403 Hz 1759.318 Hz 1762.938 Hz 1771.402 Hz 1775.313 Hz 1821.729 Hz 1990.482 Hz 2016.323 Hz 2031.448 Hz 2034.231 Hz 2050.282 Hz 2053.396 Hz 2082.234 Hz 2089.092 Hz 2221.323 Hz 2228.832 Hz 2229.515 Hz 2253.704 Hz 2254.329 Hz 2278.312 Hz 2332.949 Hz 2348.233 Hz 2381.443 Hz 2413.193 Hz 2415.243 Hz 2425.222 Hz 2433.321 Hz 2439.253 Hz 2465.23 Hz 2477.919 Hz 2669.177 Hz 2715.232 Hz 2733.843 Hz 2771.211 Hz 2802.339 Hz 2812.321 Hz 2831.386 Hz 2835.332 Hz 2851.347 Hz 2856.253 Hz 2873.542 Hz 2877.192 Hz 2885.322 Hz 2887.385 Hz 2894.972 Hz 2973.771 Hz 3080.592 Hz 3157.483 Hz 3160.321 Hz 3161.465 Hz 3185.129 Hz 3223.232 Hz 3238.148 Hz 3240.111 Hz 3249.529 Hz 3254.122 Hz 3262.145 Hz 3264.241 Hz 3265.121 Hz 3282.235 Hz 3283.392 Hz 3296.431 Hz 3314.321 Hz 3361.671 Hz 3366.311 Hz 3459.408 Hz 3461.322 Hz 3523.215 Hz 3527.233 Hz 3542.213 Hz 3590.376 Hz 3629.232 Hz 3632.793 Hz 3636.289 Hz 3637.085 Hz 3669.513 Hz 3770.189 Hz 3858.916 Hz 3872.321 Hz 3919.232 Hz 3941.739 Hz 3957.185 Hz 3975.228 Hz 3975.383 Hz 4061.131 Hz 4072.322 Hz 4139.322 Hz 4169.451 Hz 4174.259 Hz 4241.321 Hz 4243.393 Hz 4261.228 Hz 4279.113 Hz 4309.335 Hz 4314.188 Hz 4318.222 Hz 4328.928 Hz 4340.833 Hz 4380.321 Hz 4394.134 Hz 4412.252 Hz 4424.236 Hz 4439.341 Hz 4442.161 Hz 4447.221 Hz 4458.339 Hz 4556.322 Hz 4566.009 Hz 4579.981 Hz 4682.643 Hz 4718.331 Hz 4749.302 Hz 4765.331 Hz 4779.194 Hz 4912.923 Hz 4917.202 Hz 5011.325 Hz 5149.331 Hz 5228.172 Hz 5237.132 Hz 5313.353 Hz 5745.218 Hz 5757.897 Hz 5762.386 Hz 5812.322 Hz 5869.321 Hz 5882.292 Hz 5921.249 Hz 5991.932 Hz 6069.458 Hz 6071.319 Hz 6083.214 Hz 6111.819 Hz 6161.782 Hz 6169.341 Hz 6275.232 Hz 6294.929 Hz 6350.333 Hz 6356.321 Hz 6406.891 Hz 6407.207 Hz 6450.787 Hz 6477.098 Hz 6477.929 Hz 6478.338 Hz 6504.983 Hz 6543.421 Hz 6552.24 Hz 6661.09 Hz 6663.955 Hz 6753.338 Hz 6789.211 Hz 6851.323 Hz 6855.286 Hz 6875.232 Hz 6882.949 Hz 7047.223 Hz 7206.403 Hz 7232.214 Hz 7257.489 Hz 7276.209 Hz 7279.335 Hz 7281.219 Hz 7285.223 Hz 7285.693 Hz 7289.192 Hz 7326.229 Hz 7399.223 Hz 7429.212 Hz 7460.932 Hz 7480.228 Hz 7488.742 Hz 7495.763 Hz 7539.432 Hz 7564.185 Hz 7650.028 Hz 7689.728 Hz 7780.294 Hz 8021.921 Hz 8038.961 Hz 8040.322 Hz 8044.233 Hz 8054.413 Hz 8095.313 Hz 8141.174 Hz 8143.491 Hz 8164.332 Hz 8261.121 Hz 8302.285 Hz 8309.752 Hz 8372.532 Hz 8408.121 Hz 8424.229 Hz 8428.313 Hz 8430.142 Hz 8435.451 Hz 8486.421 Hz 8492.797 Hz 8548.324 Hz 8554.361 Hz 8562.965 Hz 8578.193 Hz 8579.323 Hz 8579.333 Hz 8597.409 Hz 8642.181 Hz 8655.818 Hz 8758.341 Hz 8779.323 Hz 8792.231 Hz 8819.127 Hz 8831.132 Hz 8863.232 Hz 9028.031 Hz 9049.205 Hz 9173.264 Hz 9175.311 Hz 9184.338 Hz 9186.919 Hz 9393.946 Hz 9482.409 Hz 9658.296 Hz 9737.211 Hz 9746.232 Hz 9859.322 Hz 9922.231 Hz 10020.213 Hz 10032.684 Hz 10435.191 Hz 10446.028 Hz 10449.221 Hz 10457.329 Hz 10478.221 Hz 10498.339 Hz 10545.313 Hz 10639.345 Hz 10720.221 Hz 10743.118 Hz 10813.981 Hz 10832.421 Hz 10838.243 Hz 10862.429 Hz 10865.127 Hz 10917.229 Hz 10977.188 Hz 11120.209 Hz 11143.409 Hz 11177.289 Hz 11177.409 Hz 11321.491 Hz 11359.093 Hz 11540.212 Hz 11673.031 Hz 11731.295 Hz 11793.886 Hz 11895.229 Hz 12074.531 Hz 12216.212 Hz 12223.329 Hz 12243.132 Hz 12253.329 Hz 12260.933 Hz 12262.853 Hz 12292.222 Hz 12357.353 Hz 12527.032 Hz 12668.194 Hz 12743.197 Hz 12755.333 Hz 12947.311 Hz 13477.293 Hz 13582.122 Hz 13636.082 Hz 13717.221 Hz 13756.503 Hz 13825.295 Hz 13829.195 Hz 14188.611 Hz 14410.949 Hz 14436.201 Hz 14528.429 Hz 14537.218 Hz 14563.821 Hz 14835.809 Hz 14947.184 Hz 14948.323 Hz 15429.139 Hz 15443.309 Hz 15450.183 Hz 16026.221 Hz 16062.401 Hz 16081.291 Hz 16144.343 Hz 16331.323 Hz 17316.328 Hz 17930.967 Hz 17932.432 Hz 17951.395 Hz 17970.122 Hz 18242.181 Hz 18254.323 Hz 18265.238 Hz 18337.222 Hz 18344.212 Hz 18378.321 Hz 18921.415 Hz 18926.951 Hz 18931.327 Hz 19124.197 Hz 19133.123 Hz 19321.231 Hz 19686.593 Hz 114508.332 Hz;
(4) frequencies for treatment of prostate cancer as follows
331.3 Hz 331.358 Hz 403.218 Hz 430.439 Hz 436.231 Hz 461.233 Hz 522.2 Hz 522.213 Hz 618.4 Hz 618.407 Hz 618.8 Hz 656.295 Hz 657.394 Hz 657.397 Hz 657.4 Hz 657.483 Hz 659.033 Hz 694.4 Hz 694.689 Hz 694.7 Hz 741.4 Hz 741.421 Hz 749.221 Hz 752.9 Hz 752.933 Hz 776.194 Hz 785.219 Hz 786.332 Hz 793.331 Hz 809.205 Hz 819.322 Hz 840.133 Hz 844.8 Hz 844.822 Hz 847.332 Hz 929.1 Hz 1083.309 Hz 1102.635 Hz 1102.71 Hz 1240.336 Hz 1372.934 Hz 1444.288 Hz 1486.322 Hz 1563.332 Hz 1591.322 Hz 1670.699 Hz 1697.321 Hz 1708.195 Hz 1741.939 Hz 1743.521 Hz 2031.448 Hz 2050.282 Hz 2076.519 Hz 2156.332 Hz 2229.515 Hz 2243.121 Hz 2381.443 Hz 2440.489 Hz 2475.912 Hz 2477.919 Hz 2551.332 Hz 2579.435 Hz 2628.324 Hz 2669.328 Hz 2824.832 Hz 2887.829 Hz 2891.331 Hz 3081.523 Hz 3133.309 Hz 3249.529 Hz 3250.125 Hz 3251.815 Hz 3264.827 Hz 3278.329 Hz 3281.432 Hz 3348.783 Hz 3519.118 Hz 3539.962 Hz 3551.318 Hz 3556.439 Hz 3572.321 Hz 3615.223 Hz 3670.129 Hz 3681.341 Hz 3686.021 Hz 3753.382 Hz 3774.923 Hz 3867.692 Hz 3909.333 Hz 3916.321 Hz 4031.233 Hz 4031.933 Hz 4038.203 Hz 4047.233 Hz 4066.222 Hz 4081.743 Hz 4084.319 Hz 4139.322 Hz 4153.192 Hz 4223.795 Hz 4231.221 Hz 4241.321 Hz 4320.513 Hz 4329.152 Hz 4380.321 Hz 4417.312 Hz 4489.452 Hz 4549.808 Hz 4558.306 Hz 4579.324 Hz 4638.293 Hz 4740.322 Hz 4854.318 Hz 4882.322 Hz 4978.822 Hz 5237.152 Hz 5264.222 Hz 5289.195 Hz 5426.323 Hz 5431.542 Hz 5455.593 Hz 6168.131 Hz 6345.332 Hz 6347.433 Hz 6363.284 Hz 6418.331 Hz 6496.231 Hz 6538.295 Hz 6577.421 Hz 6590.328 Hz 6651.276 Hz 6706.431 Hz 6743.322 Hz 6783.282 Hz 6850.197 Hz 6855.286 Hz 6864.896 Hz 6871.943 Hz 6878.356 Hz 6898.489 Hz 6973.393 Hz 7118.332 Hz 7120.932 Hz 7143.231 Hz 7146.509 Hz 7192.505 Hz 7251.309 Hz 7251.322 Hz 7278.124 Hz 7278.933 Hz 7279.335 Hz 7299.119 Hz 7527.229 Hz 7589.925 Hz 7699.193 Hz 7832.331 Hz 7842.184 Hz 7852.393 Hz 7872.333 Hz 8023.32 Hz 8096.939 Hz 8245.801 Hz 8315.291 Hz 8357.305 Hz 8408.121 Hz 8432.209 Hz 8535.238 Hz 8552.431 Hz 8585.224 Hz 8923.361 Hz 8935.752 Hz 9015.253 Hz 9018.233 Hz 9068.231 Hz 9137.232 Hz 9156.321 Hz 9351.931 Hz 9393.946 Hz 9694.179 Hz 9984.405 Hz 10226.223 Hz 10390.232 Hz 10442.221 Hz 10449.343 Hz 10459.084 Hz 10514.768 Hz 10651.311 Hz 10689.339 Hz 10772.419 Hz 10818.452 Hz 10843.543 Hz 11118.322 Hz 11165.239 Hz 11985.353 Hz 12209.329 Hz 12308.321 Hz 12489.233 Hz 12583.339 Hz 13820.329 Hz 14013.123 Hz 14129.213 Hz 14171.434 Hz 14681.329 Hz 14759.131 Hz 14986.794 Hz 15930.249 Hz 16026.623 Hz 16888.912 Hz 17091.189 Hz 17880.954 Hz 18021.222 Hz 18053.233 Hz 18247.532 Hz 18282.211 Hz 18610.232 Hz 18629.328 Hz 19469.318 Hz 19766.218 Hz 20159.434 Hz 21643.232 Hz 23022.481 Hz 23035.132 Hz 26718.23 Hz 30583.383 Hz 30653.323 Hz 30843.222 Hz 36065.221 Hz 60317.352 Hz;
(5) frequencies for treatment of kidney cancer as follows
628.321 Hz 631.141 Hz 643.312 Hz 812.512 Hz 826.321 Hz 1240.336 Hz 1372.934 Hz 2082.241 Hz 2156.931 Hz 2254.329 Hz 2286.5 Hz 3555.209 Hz 3928.343 Hz 4329.152 Hz 4420.932 Hz 4819.228 Hz 4828.321 Hz 5314.322 Hz 6007.332 Hz 7054.279 Hz 7074.429 Hz 7254.343 Hz 8041.289 Hz 8727.224 Hz 8760.983 Hz 8831.132 Hz 8870.228 Hz 8923.1 Hz 10565.321 Hz 10586.229 Hz 10634.293 Hz 10687.949 Hz 11421.933 Hz 11523.212 Hz 11561.221 Hz 11846.212 Hz 12631.331 Hz 12693.272 Hz 14411.321 Hz 20178.941 Hz;
(6) frequencies for treatment of thyroid cancer as follows
410.231 Hz 412.209 Hz 479.222 Hz 493.442 Hz 517.202 Hz 556.233 Hz 617.313 Hz 618.407 Hz 618.813 Hz 618.927 Hz 621.321 Hz 628.321 Hz 648.252 Hz 658.191 Hz 663.407 Hz 694.689 Hz 777.432 Hz 812.512 Hz 814.251 Hz 820.907 Hz 821.202 Hz 831.223 Hz 874.341 Hz 914.429 Hz 941.311 Hz 942.331 Hz 983.429 Hz 1127.239 Hz 1191.341 Hz 1380.828 Hz 1552.123 Hz 1587.811 Hz 1614.409 Hz 1723.389 Hz 1771.402 Hz 2155.311 Hz 2179.231 Hz 2185.282 Hz 2221.323 Hz 2228.832 Hz 2315.888 Hz 2341.312 Hz 2445.123 Hz 2454.232 Hz 2723.302 Hz 2740.384 Hz 2749.323 Hz 2856.253 Hz 2856.921 Hz 2859.495 Hz 2871.795 Hz 2886.232 Hz 2928.911 Hz 2988.212 Hz 3021.122 Hz 3078.275 Hz 3080.592 Hz 3186.331 Hz 3198.323 Hz 3248.321 Hz 3271.329 Hz 3284.192 Hz 3335.332 Hz 3432.343 Hz 3434.911 Hz 3440.212 Hz 3475.216 Hz 3509.522 Hz 3533.328 Hz 3610.203 Hz 3637.085 Hz 3682.489 Hz 3789.288 Hz 3822.392 Hz 3909.333 Hz 3917.211 Hz 4023.33 Hz 4028.204 Hz 4043.332 Hz 4046.321 Hz 4154.301 Hz 4207.322 Hz 4226.263 Hz 4236.945 Hz 4243.393 Hz 4261.228 Hz 4330.289 Hz 4340.833 Hz 4347.125 Hz 4358.333 Hz 4366.294 Hz 4426.387 Hz 4440.962 Hz 4458.339 Hz 4478.443 Hz 4479.113 Hz 4486.193 Hz 4744.424 Hz 4827.642 Hz 4854.318 Hz 4865.421 Hz 4897.212 Hz 5323.192 Hz 5324.123 Hz 5548.879 Hz 5711.283 Hz 5730.432 Hz 5754.332 Hz 5881.295 Hz 5924.221 Hz 6455.131 Hz 6558.342 Hz 6620.132 Hz 6666.839 Hz 6675.951 Hz 6714.189 Hz 6745.333 Hz 6766.281 Hz 6779.088 Hz 6780.679 Hz 6884.432 Hz 6917.194 Hz 6946.928 Hz 7036.122 Hz 7083.191 Hz 7230.838 Hz 7323.209 Hz 7355.378 Hz 7432.143 Hz 7495.763 Hz 7505.282 Hz 7534.221 Hz 7577.421 Hz 7623.184 Hz 7626.332 Hz 7725.339 Hz 7726.085 Hz 7920.879 Hz 8013.953 Hz 8019.912 Hz 8021.331 Hz 8040.231 Hz 8078.955 Hz 8082.173 Hz 8147.1 Hz 8281.259 Hz 8309.752 Hz 8311.371 Hz 8435.094 Hz 8442.293 Hz 8505.312 Hz 8521.311 Hz 8525.789 Hz 8537.321 Hz 8540.329 Hz 8543.211 Hz 8553.329 Hz 8744.527 Hz 8881.819 Hz 9009.329 Hz 9068.311 Hz 9070.809 Hz 9085.911 Hz 9535.393 Hz 9720.412 Hz 10020.521 Hz 10039.109 Hz 10127.279 Hz 10134.161 Hz 10257.324 Hz 10498.339 Hz 10765.224 Hz 10849.412 Hz 10924.342 Hz 10976.321 Hz 11030.418 Hz 11360.332 Hz 11537.292 Hz 11559.292 Hz 11812.119 Hz 11913.222 Hz 11927.934 Hz 11955.949 Hz 11960.179 Hz 12120.049 Hz 12139.222 Hz 12146.335 Hz 12489.233 Hz 12984.462 Hz 13425.229 Hz 13636.082 Hz 13654.272 Hz 13677.211 Hz 14014.941 Hz 14228.295 Hz 14445.214 Hz 14540.932 Hz 14823.325 Hz 14826.334 Hz 14910.894 Hz 15180.492 Hz 15561.322 Hz 15597.284 Hz 16023.119 Hz 16048.391 Hz 16080.831 Hz 16129.321 Hz 16539.532 Hz 17222.225 Hz 17253.222 Hz 17323.196 Hz 17461.504 Hz 17577.221 Hz 17671.321 Hz 17881.709 Hz 17911.323 Hz 17913.286 Hz 17937.203 Hz 17948.264 Hz 18036.921 Hz 18715.412 Hz 19859.429 Hz 21425.321 Hz 21452.445 Hz;
(7) frequencies for treatment of bladder cancer as follows
623.243 Hz 757.084 Hz 870.4 Hz 2454.423 Hz 2480.191 Hz 2581.101 Hz 2715.232 Hz 3042.012 Hz 3196.194 Hz 3265.323 Hz 3438.109 Hz 3692.319 Hz 3952.308 Hz 5230.227 Hz 6022.942 Hz 6061.711 Hz 6710.899 Hz 6721.912 Hz 7181.784 Hz 7212.826 Hz 7458.209 Hz 8235.21 Hz 8749.232 Hz 8767.189 Hz 9354.812 Hz 9611.339 Hz 12532.729 Hz 13467.209 Hz 13777.9 Hz 14015.241 Hz 18524.419 Hz;
(8) frequencies for treatment of colon cancer as follows
78.76 Hz 796.562 Hz 841.541 Hz 842.783 Hz 914.429 Hz 1162.117 Hz 1372.207 Hz 1372.934 Hz 1718.532 Hz 2243.169 Hz 2278.312 Hz 2286.5 Hz 2286.519 Hz 2334.178 Hz 2423.292 Hz 2454.423 Hz 2464.229 Hz 2598.853 Hz 2623.048 Hz 3131.123 Hz 3161.465 Hz 3175.313 Hz 3249.529 Hz 3363.229 Hz 3373.892 Hz 3390.925 Hz 3409.179 Hz 3432.274 Hz 3509.522 Hz 3531.422 Hz 3533.328 Hz 3766.296 Hz 4040.839 Hz 4081.022 Hz 4123.953 Hz 4146.274 Hz 4233.822 Hz 4282.332 Hz 4318.222 Hz 4344.082 Hz 4416.221 Hz 4481.242 Hz 4724.263 Hz 4751.319 Hz 4755.323 Hz 4788.485 Hz 5149.331 Hz 5217.402 Hz 5386.212 Hz 5407.192 Hz 5426.323 Hz 5496.434 Hz 5555.212 Hz 5572.032 Hz 5634.933 Hz 5724.231 Hz 5758.378 Hz 5787.342 Hz 5948.897 Hz 5967.448 Hz 5976.825 Hz 6182.322 Hz 6292.379 Hz 6324.493 Hz 6341.248 Hz 6471.322 Hz 6477.218 Hz 6558.342 Hz 6855.286 Hz 7129.843 Hz 7140.187 Hz 7162.422 Hz 7368.222 Hz 7645.859 Hz 7829.234 Hz 7866.229 Hz 7877.334 Hz 8013.314 Hz 8374.942 Hz 8384.228 Hz 8408.121 Hz 8534.111 Hz 8568.033 Hz 8573.122 Hz 9226.222 Hz 9351.9 Hz 9737.211 Hz 9744.193 Hz 9942.321 Hz 10301.371 Hz 10401.515 Hz 10872.693 Hz 11220.222 Hz 11283.378 Hz 12256.432 Hz 13749.858 Hz 15231.548 Hz 15248.324 Hz 58191.928 Hz 60317.352 Hz;
(9) frequencies for treatment of pancreas cancer as follows
331.3 Hz 331.365 Hz 436.3 Hz 436.332 Hz 447.942 Hz 476.127 Hz 559.292 Hz 589.187 Hz 624.218 Hz 727 Hz 734.921 Hz 809.313 Hz 845.309 Hz 870.4 Hz 963.221 Hz 1156.79 Hz 1157 Hz 1179 Hz 1360.133 Hz 1372.207 Hz 1372.934 Hz 1804.126 Hz 1816.221 Hz 1873.477 Hz 1967.211 Hz 1990.482 Hz 2278.312 Hz 2315.921 Hz 2320.315 Hz 2334.178 Hz 2381.443 Hz 2469 Hz 2477.919 Hz 2542.221 Hz 2598.853 Hz 2647.938 Hz 2685.081 Hz 2716.095 Hz 2721.331 Hz 2732.231 Hz 2809.849 Hz 2823.428 Hz 2835.332 Hz 3134.313 Hz 3241.461 Hz 3255.219 Hz 3263.432 Hz 3286.255 Hz 3330.935 Hz 3373.892 Hz 3438.109 Hz 3449.219 Hz 3535.219 Hz 3549.215 Hz 3564.419 Hz 3619.412 Hz 3622.312 Hz 3638.432 Hz 3696.424 Hz 3943.214 Hz 3976.929 Hz 4014.889 Hz 4041.219 Hz 4044.195 Hz 4056.384 Hz 4085.971 Hz 4144.592 Hz 4153.192 Hz 4161.889 Hz 4243.393 Hz 4332.498 Hz 4341.423 Hz 4355.327 Hz 4417.885 Hz 4422.322 Hz 4451.297 Hz 4486.384 Hz 4558.306 Hz 4580 Hz 4685.082 Hz 4839.589 Hz 5151.402 Hz 5209.911 Hz 5262.282 Hz 5271.312 Hz 5387.73 Hz 5494.928 Hz 5521.221 Hz 5573.209 Hz 5609.382 Hz 5929.616 Hz 5948.897 Hz 5966.112 Hz 5976.825 Hz 6064.197 Hz 6086.256 Hz 6157.253 Hz 6215.298 Hz 6333.917 Hz 6365.242 Hz 6558.342 Hz 6568.278 Hz 6823.194 Hz 6853.391 Hz 6855.286 Hz 7213.204 Hz 7228.528 Hz 7238.232 Hz 7277.921 Hz 7280.422 Hz 7320.494 Hz 7366.412 Hz 7534.221 Hz 7548.713 Hz 7567.127 Hz 7620.851 Hz 7663.209 Hz 7725.203 Hz 7852.233 Hz 7920.879 Hz 7985.122 Hz 8008.323 Hz 8013.312 Hz 8045.484 Hz 8242.332 Hz 8351.622 Hz 8408.121 Hz 8455.894 Hz 8551.231 Hz 8743.321 Hz 8789.631 Hz 8868.809 Hz 9012.241 Hz 9028.994 Hz 9131.232 Hz 9658.296 Hz 9663.495 Hz 9680.737 Hz 9824.442 Hz 9942.321 Hz 10279.122 Hz 10388.49 Hz 10438.495 Hz 10518.311 Hz 10528.239 Hz 10582.095 Hz 10926.111 Hz 10948.411 Hz 10955.558 Hz 11538.193 Hz 11904.741 Hz 12255.229 Hz 12613.341 Hz 12819.942 Hz 13674.482 Hz 13731.322 Hz 14525.312 Hz 14537.218 Hz 14549.331 Hz 14845.453 Hz 14944.989 Hz 15246.315 Hz 18668.239 Hz 19321.231 Hz 19347.208 Hz 30182.932 Hz;
(10) frequencies for treatment of lung cancer as follows
304.148 Hz 694.7 Hz 694.727 Hz 708.8 Hz 708.841 Hz 1587.811 Hz 1759.318 Hz 1873.477 Hz 2253.704 Hz 2391.312 Hz 2454.232 Hz 2729.929 Hz 2741.261 Hz 2761.312 Hz 2784.491 Hz 2812.443 Hz 2855.218 Hz 2859.495 Hz 3128.822 Hz 3139.297 Hz 3193.212 Hz 3348.783 Hz 3360.971 Hz 3366.311 Hz 3373.892 Hz 3440.212 Hz 3461.322 Hz 3682.489 Hz 3727.231 Hz 3749.882 Hz 3769.942 Hz 4131.235 Hz 4158.393 Hz 4243.393 Hz 4347.733 Hz 4373.411 Hz 4378.321 Hz 4416.221 Hz 4481.242 Hz 4777.521 Hz 4798.422 Hz 4837.241 Hz 4959.842 Hz 5013.321 Hz 5047.523 Hz 5068.322 Hz 5371.922 Hz 5538.432 Hz 5548.879 Hz 5679.309 Hz 5734.143 Hz 5787.342 Hz 6445.309 Hz 6838.434 Hz 6870.955 Hz 6879.216 Hz 7079.411 Hz 7216.288 Hz 7376.089 Hz 7761.289 Hz 8082.173 Hz 8281.259 Hz 8352.189 Hz 8442.473 Hz 8773.916 Hz 8935.752 Hz 9121.223 Hz 9181.434 Hz 9317.913 Hz 9363.896 Hz 9736.919 Hz 9753.321 Hz 10424.908 Hz 10452.913 Hz 10824.609 Hz 11656.329 Hz 12748.919 Hz 15774.291 Hz 15798.333 Hz 16510.333 Hz;
(11) frequencies for treatment of leiomyosarcoma as follows
836.923 Hz 843.181 Hz 1411.241 Hz 2073.721 Hz 2381.443 Hz 2711.019 Hz 2911.329 Hz 3232.185 Hz 3518.321 Hz 3544.209 Hz 3569.219 Hz 4233.822 Hz 4241.321 Hz 4266.591 Hz 4337.322 Hz 4424.112 Hz 4436.111 Hz 4485.22 Hz 5545.521 Hz 5577.841 Hz 5631.422 Hz 5696.184 Hz 6472.098 Hz 6558.342 Hz 6651.276 Hz 7168.892 Hz 7406.309 Hz 7452.528 Hz 7649.209 Hz 7808.352 Hz 9040.313 Hz 9074.294 Hz 9189.092 Hz 9484.512 Hz 9943.972 Hz 12086.394 Hz;
(12) frequencies for treatment of mesothelioma as follows
958.929 Hz 1713.913 Hz 1736.782 Hz 2334.178 Hz 2607.193 Hz 3112.974 Hz 3319.945 Hz 3449.219 Hz 3622.312 Hz 5151.402 Hz 5887.022 Hz 5965.922 Hz 6516.793 Hz 7224.197 Hz 9471.152 Hz 14617.393 Hz;
(13) frequencies for treatment of neuro-endocrine as follows
1766.335 Hz 2408.225 Hz 2441.502 Hz 2647.938 Hz 2741.261 Hz 3020.212 Hz 3128.822 Hz 3238.742 Hz 3296.431 Hz 3348.783 Hz 3360.971 Hz 3440.212 Hz 3533.328 Hz 3666.283 Hz 4079.282 Hz 4243.393 Hz 4426.387 Hz 5245.818 Hz 5536.242 Hz 5548.879 Hz 5739.422 Hz 5849.241 Hz 6291.631 Hz 6406.891 Hz 6780.679 Hz 7151.264 Hz 7482.245 Hz 7575.393 Hz 8359.932 Hz 9073.418 Hz;
(14) frequencies for treatment of leukemia and chronic lymphoid cancer as follows
814.413 Hz 825.145 Hz 2415.243 Hz 2436.316 Hz 2874.432 Hz 2891.029 Hz 3361.671 Hz 5245.452 Hz 5557.333 Hz 6850.197 Hz 6919.322 Hz 7587.224 Hz 7629.318 Hz 8172.405 Hz 8272.338 Hz 8438.453 Hz 12950.331 Hz;
(15) frequencies for treatment of myeloma as follows
765.196 Hz 2336.238 Hz 2372.122 Hz 2381.443 Hz 2425.394 Hz 2656.339 Hz 2741.261 Hz 2883.618 Hz 2919.273 Hz 3265.323 Hz 3564.455 Hz 3580.25 Hz 3584.291 Hz 3674.292 Hz 5249.331 Hz 7967.311 Hz 7973.125 Hz 8049.952 Hz 8283.329 Hz 10351.323 Hz;
(16) frequencies for treatment of lymphoma as follows
752.5 Hz 976.3 Hz 1558.223 Hz 2310.912 Hz 2477.919 Hz 2560.843 Hz 3348.783 Hz 3371.216 Hz 3605.432 Hz 3623.198 Hz 3838.281 Hz 3838.48 Hz 5102 Hz 5696.932 Hz 5724.231 Hz 6358.194 Hz 7472.211 Hz 8062.121 Hz 8222.222 Hz;
and (17) frequencies for treatment of brain cancer as follows
1372.934 Hz 2318.182 Hz 2381.443 Hz 2425.394 Hz 2442.423 Hz 2478.973 Hz 2654.513 Hz 2661.324 Hz 2686.105 Hz 2690.179 Hz 3249.332 Hz 3277.509 Hz 3335.279 Hz 3348.783 Hz 3436.211 Hz 3916.321 Hz 4031.933 Hz 4086.091 Hz 4241.321 Hz 4318.222 Hz 4334.33 Hz 4358.333 Hz 4393.419 Hz 4454.194 Hz 4515.789 Hz 4619.324 Hz 4723.937 Hz 4853.286 Hz 5289.231 Hz 5378.099 Hz 5426.323 Hz 5640.981 Hz 6316.211 Hz 6459.203 Hz 6474.332 Hz 6626.572 Hz 6855.286 Hz 6915.886 Hz 6943.386 Hz 7151.264 Hz 7182.922 Hz 7194.897 Hz 7323.209 Hz 7390.343 Hz 7796.221 Hz 7961.122 Hz 8128.942 Hz 8245.109 Hz 8272.281 Hz 8358.154 Hz 8408.121 Hz 9138.82 Hz 10719.318 Hz 11556.241 Hz 12828.633 Hz 14515.962 Hz 14586.765 Hz.
2. The system according to claim 1, wherein the frequencies of the amplitude modulations generated are controllable to within an accuracy of 100 parts per million relative to the determined or predetermined reference amplitude modulation frequencies.
3. The system according to claim 2, wherein the frequencies of the amplitude modulations generated are controllable to within an accuracy of 10 parts per million relative to the determined or predetermined reference amplitude modulation frequencies.
4. The system according to claim 3, wherein the frequencies of the amplitude modulations generated are controllable to within an accuracy of about 1 parts per million relative to the determined or predetermined reference amplitude modulation frequencies.
5. The system according to claim 1, wherein the one or more amplitude modulated low energy emissions generated are maintained at a stability during emission of at least 10−5.
6. The system according to claim 5, wherein a stability of at least 10−6 is maintained.
7. The system according to claim 6, wherein a stability of at least 10−7 is maintained.
8. The system according to claim 1, wherein said at least one controllable generator circuit is controllable by amplitude modulation control signals which lead to various forms of amplitude modulation wave forms being generated.
9. The system according to claim 8, wherein the amplitude modulation wave forms are selected from sinusoidal, square, triangular or multiple combinations thereof.
10. The system according to claim 8, wherein the at least one generator circuit is controllable by amplitude modulation control signals which generate a plurality of amplitude modulation wave forms, either sequentially or simultaneously.
11. The system according to claim 1, wherein the one or more high frequency carrier signals generated by the at least one generator circuit are selected from one or more high frequencies selected from about 27 MHz, 433 MHz and 900 MHz.
12. The system according to claim 1, wherein the system further comprises one or more interfaces communicating with the at least one data processor, and wherein the control information is transferable to said one or more interfaces and hence to the at least one data processor to enable command signals responsive to received control information to be communicated to the at least one generator circuit by the at least one data processor.
13. The system according to claim 12, wherein the control information is transferable over a communication link to the at least one data processor via the one or more interfaces communicating with the at least one data processor.
14. The system according to claim 12, wherein the control information is stored in an information storage device and wherein the control information is transferable to the at least one data processor via said one or more interfaces communicating with the at least one data processor.
15. The system according to claim 12, wherein the system further comprises a user identification device communicating with at least one of the at least one data processor to enable the system to be activated for use only by the user.
16. The system according to claim 1,
further comprising a monitor comprising monitoring software for monitoring the amplitude and the amplitude modulation frequency of the amplitude modulated low energy electromagnetic emissions generated by the at least one generator circuit.
17. The system according to claim 1, wherein the determined or predetermined amplitude modulation frequency control information is determined or predetermined by a bio-feedback process involving observations or measurements of physiological reactions by the subject during a time that cellular functions of the subject are excited by exposing the subject to emissions of high frequency carrier signals amplitude modulated at a series of amplitude modulation frequencies.
18. The system according to claim 17, wherein the determined or predetermined frequencies are employed as a mode to identify a nature of a tumor or cancer harbored by the warm-blooded mammalian subject.
US13/573,104 2007-03-27 2012-08-22 Electronic system for influencing cellular functions in a warm-blooded mammalian subject Active 2030-03-12 US8977365B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/573,104 US8977365B2 (en) 2007-03-27 2012-08-22 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07006320.1 2007-03-27
EP07006320 2007-03-27
EP07006320A EP1974769A1 (en) 2007-03-27 2007-03-27 Electronic system for influencing cellular functions in a warm-blooded mammalian subject
PCT/EP2008/002379 WO2008116640A2 (en) 2007-03-27 2008-03-26 Electronic system for influencing cellular functions in a warm-blooded mammalian subject
EPPCT/EP2008/002379 2008-03-26
US45045009A 2009-10-29 2009-10-29
US13/573,104 US8977365B2 (en) 2007-03-27 2012-08-22 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US45045009A Continuation-In-Part 2007-03-27 2009-10-29

Publications (2)

Publication Number Publication Date
US20130079853A1 US20130079853A1 (en) 2013-03-28
US8977365B2 true US8977365B2 (en) 2015-03-10

Family

ID=38117246

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/450,450 Abandoned US20100042168A1 (en) 2007-03-27 2008-03-26 Electronic system for influencing cellular functions in a warm-blooded mammalian subject
US13/573,104 Active 2030-03-12 US8977365B2 (en) 2007-03-27 2012-08-22 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/450,450 Abandoned US20100042168A1 (en) 2007-03-27 2008-03-26 Electronic system for influencing cellular functions in a warm-blooded mammalian subject

Country Status (20)

Country Link
US (2) US20100042168A1 (en)
EP (2) EP1974769A1 (en)
JP (1) JP5435240B2 (en)
KR (1) KR101474582B1 (en)
CN (1) CN101663065B (en)
AU (1) AU2008232041C1 (en)
BR (1) BRPI0810084B1 (en)
CA (1) CA2682322C (en)
DK (1) DK2139557T3 (en)
ES (1) ES2545103T3 (en)
HU (1) HUE027033T2 (en)
IL (1) IL201099A (en)
MX (1) MX2009010425A (en)
PL (1) PL2139557T3 (en)
PT (1) PT2139557E (en)
RU (1) RU2594824C2 (en)
SA (1) SA08290168B1 (en)
SI (1) SI2139557T1 (en)
WO (1) WO2008116640A2 (en)
ZA (1) ZA200906700B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075391A1 (en) 2017-10-13 2019-04-18 Costa Frederico Perego System for characterization, diagnosis, and treatment of a health condition of a patient and microtubule conductivity, and methods of using same
WO2021080947A1 (en) * 2019-10-21 2021-04-29 Therabionic Inc. Electrical system for treatment of a subject
WO2021116753A1 (en) 2019-12-11 2021-06-17 Novocure Gmbh Methods of altering the electric impedance to an alternating electric field
WO2021116748A2 (en) 2019-12-11 2021-06-17 Novocure Gmbh Compositions and methods for imaging a cell
WO2021116754A2 (en) 2019-12-11 2021-06-17 Novocure Gmbh Compositions and methods of altering the electric impedance to an alternating electric field
WO2021224687A1 (en) 2020-05-08 2021-11-11 Novocure Gmbh Compositions and methods of applying alternating electric fields to pluripotent stem cells
US11464440B2 (en) 2019-04-10 2022-10-11 Autem Medical, Llc System for prognosticating patient outcomes and methods of using the same
US11589765B2 (en) 2015-04-28 2023-02-28 Therabionic, Inc. Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
ITPD20090279A1 (en) * 2009-09-25 2011-03-26 Hypothesis Srl DEVICE FOR PREVENTING DEEP VENOUS THROMBOSIS
DE102009060543B4 (en) * 2009-12-23 2014-02-06 Axel Muntermann Method for cosmetic skin smoothing
WO2012030248A1 (en) * 2010-09-03 2012-03-08 Sajphutdinov Marat Kadirovich Electromagnetic contact-free therapy system
ITBO20110125A1 (en) * 2011-03-16 2012-09-17 Project Di Gaudenzi Valter DEVICE FOR BODY APPLICATIONS
GB2486853B (en) * 2011-04-18 2013-06-05 Freewave Ltd Therapeutic apparatus for irradiating biological cells
ITNA20110019A1 (en) * 2011-04-28 2012-10-29 Attilio Grattacaso EQUIPMENT, SYSTEM AND METHOD FOR CONTRACTION AND JOINT DIATHERMY BY MODULATION AND RADIOFREQUENCY
CN102353848B (en) * 2011-07-01 2013-08-28 大连海事大学 Electromagnetic radiation experimental system for cell
RU2514344C1 (en) * 2012-12-05 2014-04-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СамГМУ Минздрава России) Vestibuloplasty technique
WO2014164924A1 (en) * 2013-03-11 2014-10-09 NeuroEM Therapeutics, Inc. Electromagnetic treatment of brian and body disorders
US11813472B2 (en) * 2013-03-11 2023-11-14 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
US11759650B2 (en) 2013-03-11 2023-09-19 NeuroEM Therapeutics, Inc. Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment
US11752356B2 (en) 2013-03-11 2023-09-12 NeuroEM Therapeutics, Inc. Systems for controlling power to differently loaded antenna arrays
US11911629B2 (en) 2013-03-11 2024-02-27 NeurEM Therapeutics, Inc. Treatment of primary and metastatic brain cancers by transcranial electromagnetic treatment
ES2535696A1 (en) * 2013-11-13 2015-05-13 Joaquín SUROS FRIGOLA Generator of am and fm waves for the practice of electrotherapy (Machine-translation by Google Translate, not legally binding)
US11794028B2 (en) 2014-03-11 2023-10-24 NeuroEM Therapeutics, Inc. Transcranial electromagnetic treatment
US9784263B2 (en) 2014-11-06 2017-10-10 Zoll Circulation, Inc. Heat exchange system for patient temperature control with easy loading high performance peristaltic pump
US11359620B2 (en) 2015-04-01 2022-06-14 Zoll Circulation, Inc. Heat exchange system for patient temperature control with easy loading high performance peristaltic pump
US11116657B2 (en) 2017-02-02 2021-09-14 Zoll Circulation, Inc. Devices, systems and methods for endovascular temperature control
US11185440B2 (en) 2017-02-02 2021-11-30 Zoll Circulation, Inc. Devices, systems and methods for endovascular temperature control
KR101845017B1 (en) * 2017-07-21 2018-04-03 주식회사 비엠텍월드와이드 High frequency oral therapeutic apparatus
TWI811495B (en) * 2018-12-03 2023-08-11 美商Aah控股有限責任公司 Apparatus and method for treatment of mental and behavioral conditions and disorders with electromagnetic fields

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649935A (en) 1984-05-21 1987-03-17 Symtonic Sa Method of treating neurovegetative disorders and apparatus therefor
EP0592851A2 (en) 1992-09-25 1994-04-20 Symtonic S.A. Method and system for applying low energy emission therapy
US5690692A (en) 1995-10-11 1997-11-25 Regeneration Technology Bio-active frequency generator and method
RU2112563C1 (en) 1995-03-14 1998-06-10 Синицын Лев Николаевич Method for treating purulent wounds
RU2127616C1 (en) 1998-02-03 1999-03-20 Закрытое акционерное общество НЦИМ "ЛИДО" Device for millimeter-wave therapy
US5891182A (en) 1995-10-11 1999-04-06 Regeneration Tech Bio-active frequency generator and method
US5908441A (en) 1997-01-16 1999-06-01 Bare; James E. Resonant frequency therapy device
US6167304A (en) 1993-05-28 2000-12-26 Loos; Hendricus G. Pulse variability in electric field manipulation of nervous systems
EP1070518A2 (en) 1999-07-19 2001-01-24 Sherwood Services AG Modulated high frequency tissue modification
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP2006167117A (en) 2004-12-15 2006-06-29 Toshiba Corp Radiation therapy management system
US8192969B2 (en) 1998-06-24 2012-06-05 Santi Tofani Apparatus and method for interfering with pathological cells survival processes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07171222A (en) * 1993-12-21 1995-07-11 Olympus Optical Co Ltd Thermotherapeutic apparatus
US6530630B2 (en) * 2001-07-13 2003-03-11 Carrier Corporation Panel seal for an air handling unit

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649935A (en) 1984-05-21 1987-03-17 Symtonic Sa Method of treating neurovegetative disorders and apparatus therefor
US4765322A (en) 1984-05-21 1988-08-23 Symtonic Sa Method of treating neurovegetative disorders and apparatus therefor
EP0592851B1 (en) 1992-09-25 2001-12-05 Symtonic S.A. System for applying low energy emission therapy
US5441528A (en) 1992-09-25 1995-08-15 Symtonic, S.A. Method and system for applying low energy emission therapy
EP0592851A2 (en) 1992-09-25 1994-04-20 Symtonic S.A. Method and system for applying low energy emission therapy
JPH07546A (en) 1992-09-25 1995-01-06 Symtonic Sa Method and system to perform low energy emission therapy
US6167304A (en) 1993-05-28 2000-12-26 Loos; Hendricus G. Pulse variability in electric field manipulation of nervous systems
RU2112563C1 (en) 1995-03-14 1998-06-10 Синицын Лев Николаевич Method for treating purulent wounds
US5891182A (en) 1995-10-11 1999-04-06 Regeneration Tech Bio-active frequency generator and method
US5690692A (en) 1995-10-11 1997-11-25 Regeneration Technology Bio-active frequency generator and method
US5908441A (en) 1997-01-16 1999-06-01 Bare; James E. Resonant frequency therapy device
RU2127616C1 (en) 1998-02-03 1999-03-20 Закрытое акционерное общество НЦИМ "ЛИДО" Device for millimeter-wave therapy
US8192969B2 (en) 1998-06-24 2012-06-05 Santi Tofani Apparatus and method for interfering with pathological cells survival processes
EP1070518A2 (en) 1999-07-19 2001-01-24 Sherwood Services AG Modulated high frequency tissue modification
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
JP2006167117A (en) 2004-12-15 2006-06-29 Toshiba Corp Radiation therapy management system

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Alexandre Barbault et al: Journal of Experimental & Clinical Cancer Research 2009, 28:51, Article entitled Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach, published Apr. 14, 2009.
B. Pasche, A. Barbault: "Low-Energy Emission Therapy: Current Status and Future Directions"; In Bioelectromagnetic Medicine, P. J. Rosch, M. S. Markov (eds), pp. 321-327; Marcel Dekker, Inc., New York, New York, 2003.
B. Pasche, M. Erman, R. Hayduk, M. Mitler, M. Reite, L. Higgs, U. Dafni, D. Amato, C. Rossel, N. Kuster, A. Barbault, J. P. Lebet: "Effects of Low Energy Emission Therapy in Chronic Psychophysiological Insomnia"; Sleep 19, pp. 327-336, 1996.
D. Amato, B. Pasche: "An Evaluation of the Safety of Low Energy Emission Therapy"; Compr Ther 19, pp. 242-247, 1993.
Higgs, M. Reite, A. Barbault, J. P. Lebet, C. Rossel, D. Amato, U. Dafni, B. Pasche: "Subjective and Objective Relaxation Effects of Low Energy Emission Therapy"; Stress Medicine 10, pp. 5-13, 1994.
J. A. Koziol, M. Erman, B Pasche, R. Hajdukovic, M. M. Mitler: "Assessing a Changepoint in a Sequence of Repeated Measurements With Application to a Low-Energy Emission Therapy Sleep Study"; J. Applied Statistics 20, pp. 393-400, 1993.
J. P. Lebet, A. Barbault, C. Rossel, Z. Tomic, M. Reite, L. Higgs, U. Dafni, D. Amato, B. Pasche: Electroencephalographic Changes Following Low Energy Emission Therapy; Ann Biomed Eng 24, pp. 424-429, 1996.
L. Cordesses: "Direct Digital Synthesis: A Tool for Periodic Wave Generation (Part 1)"; IEEE Signal Processing Magazine, IEEE Service Center, Piscataway, New Jersey, US, vol. 21, No. 4, Jul. 2004, pp. 50-54, XP011115196.
M. Reite, L. Higgs, J. P. Lebet, A. Barbault, C. Rossel, N. Kuster, U. Dafni, D. Amato, B. Pasche: "Sleep Inducing Effect of Low Energy Emission Therapy"; Bioelectromagnetics 15, pp. 67-75, 1994.
T. L. Kelly, D. F. Kripke, R. Hayduk, D. Ryman, B. Pasche, A. Barbault: "Bright Light and LEET Effects on Circadian Rhythms, Sleep and Cognitive Performance"; Stress Medicine 13, pp. 251-258, 1997.

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11589765B2 (en) 2015-04-28 2023-02-28 Therabionic, Inc. Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient
WO2019075391A1 (en) 2017-10-13 2019-04-18 Costa Frederico Perego System for characterization, diagnosis, and treatment of a health condition of a patient and microtubule conductivity, and methods of using same
US11464440B2 (en) 2019-04-10 2022-10-11 Autem Medical, Llc System for prognosticating patient outcomes and methods of using the same
WO2021080947A1 (en) * 2019-10-21 2021-04-29 Therabionic Inc. Electrical system for treatment of a subject
WO2021116753A1 (en) 2019-12-11 2021-06-17 Novocure Gmbh Methods of altering the electric impedance to an alternating electric field
WO2021116748A2 (en) 2019-12-11 2021-06-17 Novocure Gmbh Compositions and methods for imaging a cell
WO2021116754A2 (en) 2019-12-11 2021-06-17 Novocure Gmbh Compositions and methods of altering the electric impedance to an alternating electric field
WO2021224687A1 (en) 2020-05-08 2021-11-11 Novocure Gmbh Compositions and methods of applying alternating electric fields to pluripotent stem cells

Also Published As

Publication number Publication date
CN101663065A (en) 2010-03-03
EP2139557A2 (en) 2010-01-06
IL201099A (en) 2014-05-28
RU2009139633A (en) 2011-05-10
CN101663065B (en) 2014-04-16
US20130079853A1 (en) 2013-03-28
JP2010522051A (en) 2010-07-01
PL2139557T3 (en) 2015-10-30
CA2682322A1 (en) 2008-10-02
DK2139557T3 (en) 2015-08-10
EP1974769A1 (en) 2008-10-01
BRPI0810084B1 (en) 2016-04-12
HUE027033T2 (en) 2016-08-29
RU2594824C2 (en) 2016-08-20
CA2682322C (en) 2015-07-14
AU2008232041A2 (en) 2010-03-25
IL201099A0 (en) 2010-05-17
BRPI0810084A2 (en) 2014-03-18
JP5435240B2 (en) 2014-03-05
PT2139557E (en) 2015-09-23
ZA200906700B (en) 2010-11-24
KR101474582B1 (en) 2014-12-19
WO2008116640A2 (en) 2008-10-02
AU2008232041C1 (en) 2014-02-20
AU2008232041A1 (en) 2008-10-02
WO2008116640A3 (en) 2008-11-27
KR20100015970A (en) 2010-02-12
EP2139557B1 (en) 2015-05-13
SA08290168B1 (en) 2013-04-30
ES2545103T3 (en) 2015-09-08
MX2009010425A (en) 2009-12-14
SI2139557T1 (en) 2015-10-30
AU2008232041B2 (en) 2013-11-14
US20100042168A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
US8977365B2 (en) Electronic system for influencing cellular functions in a warm-blooded mammalian subject
JP7125033B2 (en) Methods and devices for aesthetic treatment of biological structures with radio frequency and magnetic energy
CN108064147B (en) Hemodynamic parameter (HDP) monitoring system for diagnosing a health condition of a patient
US6142927A (en) Method and apparatus for treatment with resonant signals
JP2006519680A (en) Electromagnetic therapy device and method
Habibagahi et al. Vagus nerve stimulation using a miniaturized wirelessly powered stimulator in pigs
US20200289841A1 (en) System and method for therapeutic treatment using light and pulse modulation
Al-Mandeel et al. Pulsed and continuous short-wave therapy
US20220379130A1 (en) Electrical system for treatment of a subject
RU2799358C2 (en) Methods and devices for aesthetic therapy of biological structures using radio frequency and magnetic energy
RU2134597C1 (en) Apparatus for microwave therapy
JP2001517975A (en) Therapeutic device and method
Urbina et al. Electromagnetic Susceptibility of Implan table Medical Devices: An Experimental Assessment
CN109806502A (en) A kind of heart medical physiotherapy device
RU2295988C2 (en) Method and device for carrying out electromagnetotherapy
CN101332337A (en) Physiotherapy therapeutic equipment and operation method thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: THERABIONIC, LLC, ALABAMA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PASCHE, BORIS, MR.;BARBAULT, ALEXANDRE, MR.;SIGNING DATES FROM 20140209 TO 20140210;REEL/FRAME:032179/0915

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8